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3Abstract 
Hepatitis E virus (HEV) is a non-enveloped RNA virus with a single-stranded, positive-sense 
genome, currently classified in the family Hepeviridae, and within in, proposedly in the genus 
Orthohepevirus. HEV infections are common in both humans and animals. In humans, HEV 
genotypes 1 and 2 (HEV-1 and HEV-2) are endemic to Asia, Africa, and Central America, where 
they cause large, usually waterborne, hepatitis epidemics, whereas zoonotic genotypes 3 and 4 
(HEV-3 and HEV-4) cause sporadic cases worldwide. HEV-3 and HEV-4 also infect animals, and 
especially HEV-3 is common in swine globally. The porcine infection is usually asymptomatic. In 
humans, HEV-3 and HEV-4 infections are often asymptomatic or only cause mild symptoms of 
hepatitis, but they can also cause chronic hepatitis that can lead to liver fibrosis and cirrhosis and 
even death in immunocompromised patients. In this work, the presence of HEV and antibodies 
against HEV were confirmed in both humans and domestic pigs in Finland. 
 
Antibodies against HEV were present in 27.6% of human patients diagnosed with acute non-A–C 
hepatitis and as a marker for acute hepatitis E infection, anti-HEV IgM antibodies in 11.3% of the 
patients. All HEV isolates obtained from the patients belonged to HEV-1. Most of the patients 
with acute infections had recently visited HEV-1 endemic areas in Asia, Africa, or Mexico, 
indicating that their infections were obtained during travels. However, the possibility of infections 
acquired in Finland could not be excluded, since no traveling data were available for several HEV-
positive patients. 
 
Of all production pigs of different ages investigated, from sucker-aged pigs to sows, 20.7% were 
positive for HEV RNA and 86.3% for antibodies against HEV. In total, samples positive for HEV 
RNA or anti-HEV antibodies were detected from 56.8% of separate swine farms investigated. 
Longitudinal follow-up studies on pigs at farrowing and fattening stages revealed that the pigs 
were infected with HEV at the age of 2–3 months, when the prevalence of HEV RNA-positive 
pigs was at its peak, 34.6%. Thereafter, the prevalence of HEV RNA-positive pigs declined to 
21.1% at 3–4 months of age and to 2.9% in finisher pigs aged 5 months or older. High anti-HEV 
antibody seroprevalences of over 80% were detected in all age groups tested, from weaner-aged 
pigs to sows, indicating that hepatitis E infections are very common in production pigs in Finland. 
All HEVs from pigs were of HEV-3, subtype e. Genetically separate clusters of HEV isolates were 
obtained from different swine farms, suggesting that genetic variations in viruses from different 
locations occur. In addition, two different isolates were obtained from the same farm. In the 
follow-up studies, pig-to-pig transmission of HEV was observed. The pigs were commonly 
shedding HEV at the time they were transferred from farrowing farms to fattening farms, creating 
a possible risk of zoonotic infection for pig handlers. When pigs from HEV-negative and HEV-
positive farms arrive at the same fattening farm, infection at a later age during the fattening stage 
must also be considered possible, which constitutes a risk for HEV entering the food chain in pork 
at the time of slaughter. 
 
Antibodies against HEV are common in Finnish veterinarians, with an apparent seroprevalence of 
10.2%. In statistical analysis of different background and risk factors related to veterinary work, 
HEV seropositivity was unexpectedly associated with working as a small animal practitioner and 
4negatively associated with having contacts with swine. However, contradictory to swine contacts, 
the seroprevalence appeared to be higher in those who had had needle stick by a needle that had 
previously been injected into a pig than in those who had not, suggesting that contact with blood or 
tissue fluid from swine might be a risk factor for HEV infection in veterinarians. In addition, those 
small animal practitioners who had traveled outside Europe during the previous five years 
appeared to be more often seropositive than those who had not, suggesting that some infections 
might have been travel-related. Although pigs seem to play a role in the hepatitis E infections of 
veterinarians, there are possibly multiple factors involved, including also other reservoirs of HEV 
than pigs. 
 
HEV must be considered a possible cause of acute hepatitis in humans in Finland, especially in 
patients who have returned from areas endemic to HEV-1 and HEV-2. Although no human cases 
of possibly zoonotic HEV-3 infections acquired in Finland were detected in this study, their 
possibility should not be overlooked since HEV is widespread in production pigs in Finland and 
routes for zoonotic infection exist. 
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Introduction 
Hepatitis E virus (HEV) infections occur in both humans and animals worldwide. The human 
disease, hepatitis E, manifests as two distinct diseases with different epidemiological and clinical 
features (Teshale et al., 2010b). HEV genotypes 1 and 2 (HEV-1 and HEV-2) only infect humans 
and are endemic to Asia, Africa, and Central America, where they cause enterically transmitted, 
usually waterborne epidemics of hepatitis E, and the disease is referred to as the endemic disease 
(Balayan et al., 1983; Aggarwal, 2010; Teshale et al., 2010b). HEV genotypes 3 and 4 (HEV-3 and 
HEV-4) are zoonotic and occur worldwide (Meng et al., 1997; Schlauder et al., 1998; Okamoto et 
al., 2007). In addition to humans, they also infect several different animal species (Smith et al., 
2014). In humans, they cause sporadic cases of hepatitis E, referred to as the sporadic or zoonotic 
disease (Teshale et al., 2010b).  
 
The existence of HEV was first suspected in 1978 during a large waterborne hepatitis epidemic in 
India (Khuroo, 1980). The disease was transmitted enterically, it spread from person to person, 
occurred in adults, and had a high attack rate and mortality among pregnant women (Khuroo, 
1983). The causative agent was discovered in 1983 by Balayan and colleagues (1983) by immune 
electron microscopy. The full-length genome of HEV, which is a non-enveloped, single-stranded 
RNA virus with a positive sense genome, was sequenced in 1991 (Tam et al., 1991).  
 
In addition to occurring in humans, the presence of HEV in animals was demonstrated in pigs in 
1995 (Clayson et al., 1995a), and the first animal strain of HEV was isolated from pigs in 1997 
(Meng et al., 1997). Since then, especially HEV-3 has been isolated from several species of 
mammals, including wild boars (Sonoda et al., 2004), different species of deer (Tei et al., 2003; 
Reuter et al., 2009; Forgách et al., 2010), rabbits (Zhao et al., 2009) and rats (Johne et al., 2010a). 
HEV-4 has been principally isolated in different animal species in China (Zhang et al., 2008b). In 
addition, new genotypes of HEV and HEV-like viruses with unknown potential for zoonosis have 
been found in several other animal species, including ferrets (Raj et al., 2012), moose (Lin et al., 
2014), camels (Woo et al., 2014), and fish (Batts et al., 2011). HEV and HEV-like viruses are 
currently classified in the family Hepeviridae (Emerson et al., 2004), and within it, HEV isolates 
from humans, other mammalian species, and chicken are proposedly classified in the genus 
Orthohepevirus, and isolates from fish in the genus Piscihepevirus (Smith et al., 2014). 
 
In swine, HEV-4 and especially HEV-3 are enzootic worldwide (Okamoto et al., 2007). Since the 
discovery of swine HEV, it has been shown to be common in production pigs. In the USA, 100% 
of adult pigs in some swine herds had antibodies against HEV (Meng et al., 1997), and HEV 
RNA-positive pigs have been detected in up to 100% of farms investigated in Italy and the UK (Di 
Bartolo et al., 2008; McCreary et al., 2008). Different HEV seroprevalences have been reported in 
slaughter-aged pigs in Europe, ranging from 31% (Rose et al., 2011) to 88% (Jori et al., 2016), 
with variations, including HEV-seronegative farms, observed between the farms investigated 
(Walachowski et al., 2013). 
 
The main route of HEV transmission in pigs is fecal-oral, and the porcine infection is usually 
asymptomatic (Meng et al., 1997). Acute infections with fecal shedding of HEV are most common 
14
in pigs aged 2–4 months (Cooper et al., 2005). In the feces and livers of slaughter-aged pigs, HEV 
RNA has been detected with rates ranging from 0% (Kaba et al., 2009; Kanai et al., 2010; Casas et 
al., 2011a) to 41.2% (Leblanc et al., 2007) and from 4% (Rose et al., 2011) to 75% (Walachowski 
et al., 2013), respectively, showing potential sources of foodborne infections via pork and pork-
derived products, and of zoonotic infections for persons in contact with slaughtered pigs. 
 
Zoonotic hepatitis E infections of foodborne origin have been linked to consumption of pig, wild 
boar, and deer meats and entrails, mostly uncooked or undercooked products (Matsuda et al., 
2003; Li et al., 2005b; Mizuo et al., 2005; Matsubayashi et al., 2008; Renou et al., 2014), but also 
cooked pork and wild boar meat (Tei et al., 2003; Riveiro-Barciela et al., 2015). Persons in contact 
with swine, such as swine farm workers, swine veterinarians, and slaughterhouse workers, have 
been reported to have antibodies against HEV more often than control persons with no exposure to 
pigs (Drobeniuc et al., 2001; Meng et al., 2002; Bouwknegt et al., 2007; Christensen et al., 2008; 
Galiana et al., 2008; Krumbholz et al., 2012, 2014; Chaussade et al., 2013; Lange et al., 2016; 
Teixeira et al., 2016). In addition, HEV-3 has been isolated from mussels (Crossan et al., 2012; 
Mesquita et al., 2016), and consumption of shellfish and contact with raw sea food have been 
associated with acute HEV infections (Said et al., 2009; Cui et al., 2015). 
 
The aim of this doctoral thesis was to investigate the occurrence of HEV in human patients with 
acute, unexplained non-A–C hepatitis, in production swine, and in veterinarians in Finland, where 
no previous investigations of HEV had been conducted. Specific aims were to investigate 
transmission of HEV and dynamics of the infection among production swine during their 
production cycle, to evaluate the work-related risk factors associated with HEV exposure in 
Finnish veterinarians, and to examine the possibility of zoonotic swine-to-human HEV infections 
in Finland. 
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2   Review of the literature 
2.1   Discovery and history of hepatitis E virus (HEV) 
Hepatitis E virus was discovered in 1983 by Balayan and colleagues (1983) by immune electron 
microscopy. Before that, in 1978, suspicions about the existence of a new hepatitis virus were 
raised by Khuroo (1980) during a large waterborne epidemic of jaundice with over 600 000 
affected people in Kashmir, India. At this point, two causative agents for infectious viral hepatitis 
were already known: hepatitis A virus (HAV) and hepatitis B virus (HBV), responsible for two 
separate clinical diseases (Aggarwal, 2011). The possible new form of infectious hepatitis, referred 
to as non-A, non-B hepatitis, was characterized by a high attack rate and mortality among pregnant 
women, and the studies of Khuroo (1980) showed that only one of the tested serum samples from 
patients showed antibodies against HBV, and detected antibodies against HAV originated from 
previous exposure to or vaccination against HAV. In addition, the disease was transmitted 
enterically, spread from person to person, occurred in adults, and did not cause chronic liver 
infection (Khuroo et al., 1983). A few months later, Wong and colleagues (1980) reported results 
of their serological testing of samples collected during a large outbreak of hepatitis in New Delhi, 
India in 1955–1956, in addition to two smaller outbreaks in India in 1975–1976 and 1978–1979. 
The disease had similar characteristics, in addition to the waterborne origin, as that described by 
Khuroo (1980), suggesting that they were caused by the same non-A, non-B hepatitis virus. In the 
following years, waterborne epidemics of similar hepatitis, which came to be known as epidemic 
non-A, non-B hepatitis or enterically transmitted non-A, non-B (ENANB) hepatitis, were also 
reported from Nepal, Algeria, Burma, Pakistan, and Mexico (Kane et al., 1984; Belabbes et al., 
1985; Hla et al., 1985; Leads from the MMWR, 1987; Smego and Khaliq, 1988; Velázquez et al., 
1990). 
Balayan and colleagues (1983) investigated an outbreak of this disease among Soviet military 
recruits in an army camp in Afghanistan. Balayan transmitted the disease to himself by ingesting 
pooled stool extracts of the patients, and following that, developed typical clinical symptoms of 
the acute non-A, non-B hepatitis. Approximately one month after the infection, he identified 
spherical virus-like particles (VLPs) of 27–34 nm in diameter in his stool samples by immune 
electron microscopy. However, cloning and sequencing of the virus did not succeed for several 
years due to the fewness of viral particles in the samples of infected patients. Later, Reyes and 
colleagues (1990) succeeded in partially cloning the virus, which had by that time been named 
hepatitis E virus (HEV), from bile obtained from an experimentally infected cynomolgus macaque. 
Before the successful cloning, and naming, of HEV, another non-A, non-B hepatitis virus, 
hepatitis C virus (HCV) was cloned (Choo et al., 1989; Kubo et al., 1989), and also the delta agent, 
or hepatitis D virus (HDV), had been discovered (Rizzetto et al., 1980), leading to hepatitis E virus 
being named with the letter ´E´. In addition, the letter ´E´ makes reference to the enteric, endemic 
and epidemiologic characteristics of the disease (Pérez-Gracia et al., 2016). A year later, the full-
length genome of HEV was sequenced by Tam and colleagues (1991), and an enzyme 
immunoassay for detection of antibodies against HEV was developed by Yarbough and colleagues 
(1991). 
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Since the 1990s, intensified research of hepatitis E virus and its occurrence has led to a better 
understanding of the virus and the disease that it causes. In addition to occurring in humans, 
HEV´s presence in animals was demonstrated for the first time in 1995, when Clayson and 
colleagues (1995a) detected HEV RNA in pigs in Nepal. However, that RNA was not sequenced, 
and the first animal strain of HEV was isolated from a pig in the USA two years later by Meng and 
colleagues (1997). Since then, HEV and HEV-like viruses have been isolated from several species 
of mammals, birds, and fish (Hasqhenas et al., 2001; Tei et al., 2003; Nakamura et al., 2006; Saad 
et al., 2007; Zhang et al., 2008; Reuter et al., 2009; Zhao et al. 2009; Forgách et al., 2010; Johne et 
al., 2010a; Batts et al., 2011; Drexler et al., 2012; Raj et al., 2012; Yamamoto et al., 2012; 
Bodewes et al., 2013; Guan et al., 2013; Krog et al., 2013; Lin et al., 2014; Woo et al., 2014; Xu et 
al., 2014; Kubankova et al., 2015; Di Martino et al., 2016). 
2.2   Structure and genome of HEV 
HEV is a non-enveloped RNA virus (Reyes et al., 1990) with a spherical virion of approximately 
27–34 nm in diameter (Balayan et al., 1983; Kane et al., 1984; Sreenivasan et al., 1984; Bradley et 
al., 1988). The virion has icosahedral symmetry (Xing et al., 1999) and has spikes and indentations 
on the surface (Bradley et al., 1987; Arankalle et al., 1988).  
The genome of HEV is a positive sense, single-stranded RNA particle of approximately 7.5 
kilobases in size (Tam et al., 1991), and it consists of three open reading frames (ORFs), ORF1, 
ORF2, and ORF3, with partial overlap (Tam et al., 1991) (Figure 1). The genome is capped at the 
5’ end (Kabrane-Lazizi et al., 1999), where there is also a short non-coding region of 28 
nucleotides (nt). ORF1, which is the largest of the ORFs of HEV, begins at the 5’ end of the 
genome and terminates at nt position 5109 (Panda et al., 2007). It encodes nonstructural proteins, 
including methyltransferase, papain-like cysteine protease, RNA helicase, and RNA-dependent 
RNA polymerase (Koonin et al., 1992; Emerson and Purcell, 2007). ORF2 extends from nt 
position 5147 to nt position 7127 (Panda et al., 2007) and encodes a glycoprotein that forms the 
capsid of the virus (Jameel et al., 1996). The shortest ORF, ORF3, overlaps ORF1 by one nt at its 
5’ end in genotypes HEV-1–HEV-3 and significantly overlaps ORF2, extending from nt position 
5107 to nt position 5472. In the genome of HEV-4, ORF-3 only overlaps ORF2 (Panda et al., 
2007). ORF-3 encodes a phosphoprotein that takes part in the intracellular regulation of the virus 
(Zafrullah et al., 1997) and promotes replication and pathogenesis (Chandra et al., 2008). At the 3’ 
end of the genome, there is an untranslated region of 68 nt that terminates at a polyadenylated tail 
of approximately 150–200 nt (Tam et al., 1991).  
Figure 1. Genome organization of HEV-1–HEV-3 from 5 ´end to 3´ end. Met, methyltransferase; 
Y, Y domain; PCP, papain-like cysteine protease; HVR, hypervariable region; X, macro domain; 
Hel, RNA helicase; RdRp, RNA-dependent RNA polymerase. 
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2.3   Classification and taxonomy of HEV 
After its discovery, HEV was initially suggested to group taxonomically into the Picornaviridae 
family (Miller et al., 1995), since it morphologically resembled picornaviruses (Sreenivasan et al., 
1984). However, HEV turned out to be antigenically and biophysically unrelated to picornaviruses, 
and based on biophysical characterization of its viral particle, it was next hypothesized to be a 
calicivirus-like virus (Bradley et al., 1988; Tam et al., 1991). Thus, it was tentatively classified 
into the family Caliciviridae, under a separate genus Hepevirus (Kabrane-Lazizi et al., 1999; 
Panda et al., 2007). Later, however, it was observed that the order of the genes of HEV differed 
from that of typical caliciviruses and it was removed from the Caliciviridae family (Pringle et al., 
1998; Green et al., 2000). Following this, HEV was classified in a separate unassigned genus 
‘Hepatitis E-like viruses’ (Fauquet and Mayo, 2001), until it was classified as the type species of a 
new genus Hepevirus in the family Hepeviridae (Emerson et al., 2004). The latest proposal of 
taxonomy of HEV keeps it in the family Hepeviridae, but within it, classifies it in the genus 
Orthohepevirus and the species Orthohepevirus A, which includes human and swine HEV isolates, 
in addition to HEVs from several other mammal species (Smith et al., 2014). The genus 
Orthohepevirus also includes the species Orthohepevirus B, Orthohepevirus C, and 
Orthohepevirus D, which consist of HEVs and HEV-like viruses from both mammal species and 
chickens. Another genus under the family Hepeviridae is Piscihepevirus, which consists of HEV-
like viruses from trout (Smith et al., 2014). 
2.4   HEV genotypes 
Traditionally, the HEVs infecting mammal species have been divided into four genotypes: HEV-1, 
HEV-2, HEV-3, and HEV-4 (Lu et al., 2006). In addition, HEV isolated from the chicken, i.e. 
avian HEV (Hasqhenas et al., 2001), has constituted a genotype of its own (Lu et al., 2006). 
During the last ten years, additional, possible new genotypes of HEV have been found from 
several animal species, resulting in Smith and colleagues (2014) proposing, in addition to the 
above-mentioned new classification of the family Hepeviridae, a new genotype division of HEV 
and HEV-like viruses presented in Table 1. This proposal designated five new HEV genotypes: 
genotypes HEV-5 and HEV-6 isolated from wild boars and HEV-7 isolated from camels in the 
species Orthohepevirus A, and genotypes C-1 and C-2 isolated from rats and ferrets, respectively, 
in the species Orthohepevirus C. Genotypes were not assigned for HEV isolates from chickens and 
bats, but they were both classified into species of their own: Orthohepevirus B and Orthohepevirus 
D, respectively. In addition, HEV-like viruses isolated from trouts were classified into a genus of 
their own, Piscihepevirus.  
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Table 1. Current, proposed classification and genotype division of HEV according to Smith et al. 
(2014). 
Family Genus Species Genotype 
Most common    
host species 
Hepeviridae Orthohepevirus Orthohepevirus A HEV-1 Human 
   HEV-2 Human 
   HEV-3 Human, pig,         
   HEV-4 Human, pig 
   HEV-5 Wild boar 
   HEV-6 Wild boar 
   HEV-7 Camel 
  Orthohepevirus B  Chicken 
  Orthohepevirus C C-1 Rat 
   C-2 Ferret 
  Orthohepevirus D  Bat 
 Piscihepevirus Piscihepevirus A  Trout 
HEV-1 and HEV-2 only infect humans. HEV-1 is endemic to Africa and Asia, whereas isolates of 
HEV-2 have been isolated in Mexico and Africa. HEV-3 and HEV-4 are zoonotic and can infect 
both humans and animals. HEV-3 is distributed worldwide in humans and swine. In Europe, where 
it is the most frequently isolated genotype, it has been isolated from humans in several countries 
(Lapa et al., 2015), including Finland (Kettunen et al., 2013). In addition to swine, HEV-3 has also 
been frequently isolated from wild boars (Sonoda et al., 2004; de Deus et al., 2008b; Kaci et al., 
2008; Martelli et al., 2008; Rutjes et al., 2010; Widén et al., 2011; Mesquita et al., 2014a; Ivanova 
et al., 2015) and several other animal species, most often in rabbits and different species of deer 
(Tei et al., 2003; Reuter et al., 2009; Zhao et al., 2009; Forgách et al., 2010). HEV-4 has most 
frequently been isolated in Asia, in China, Japan, Taiwan, and Vietnam in both humans and 
animals (Lapa et al., 2015), but also in Europe in pigs in Belgium (Hakze-van der Honing et al., 
2011) and in both humans and pigs in Italy (Garbuglia et al., 2013; Monne et al., 2015). In 
addition to swine, HEV-4 has also been detected in wild boars (Kim et al., 2010; Sato et al., 2011) 
and in several other animal species in China (Zhang et al., 2008a; Xu et al., 2014; Thiry et al., 
2015a). 
 
On a nucleotide level, HEV-1 and HEV-2 isolates share a similarity of approximately 75%, as do 
HEV-3 and HEV-4 isolates (Lu et al., 2006). The newly identified isolates from different animal 
species are more distant from each other and from the HEV isolates from humans. The nucleotide 
similarities between the trout HEV-like virus (Piscihepevirus), avian HEV (Orthohepevirus B), rat 
HEV (genotype C-1), and human HEVs range between 38% and 57% (Batts et al., 2011). The 
HEV-like viruses from bats (Orthohepevirus D) share similarities of 13–52% with HEVs from 
other species, the lowest similarity with the trout HEV-like virus and the highest with human 
HEV-1 (Drexler et al., 2012). The genome of ferret HEV (genotype C-2) shared a 73% similarity 
with rat HEV and lower similarities of 55–61% with HEV-1–HEV-4 and avian HEV (Raj et al., 
2012). The HEV-7 from camels shared nucleotide similarities of 48–76% with other known HEV 
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genotypes, the lowest similarity with the trout HEV-like virus and the highest with HEV-3 isolated 
from deer (Woo et al., 2014). Despite the genetic heterogeneity of HEV, it appears that all 
genotypes, or at least HEV-1–HEV-4, belong to the same serotype (Arankalle et al., 1995). 
 
HEV-1–HEV-7 are further divided into subtypes according to Lu and colleagues (2006) and more 
recently according to Smith and colleagues (2016). Furthermore, Smith and colleagues (2016) 
proposed reference sequences for the subtypes of HEV-1–HEV-7. Based on their phylogenetic 
analyses, HEV-1 is divided into six (1a–1f), HEV-2 into two (2a and 2b), HEV-3 into ten (3a–3j), 
and HEV-4 into nine subtypes (4a–4i). The subtypes of HEV-3 have been shown to form two 
major clades: 3abchij and 3efg (Doceul et al., 2016; Smith et al., 2016). Lu et al. (2006) assigned 
nucleotide differences of HEV sequences at genotype, subtype and isolate levels and they are the 
most commonly used and generally accepted for differentiation of HEV sequences, and later 
analyses have been based on them. According to Lu et al. (2006), the differences for HEV-3 and 
HEV-4 are at genotype level 18.8–28.2%, at subtype level 11.4–22.8%, and at isolate level 2.0–
14.8%, depending on the part of the genome sequenced. A recent study by Doceul and colleagues 
(2016) demonstrated that within the HEV-3 subtype clade 3abchij, the difference between the 
subtypes was 3.5–17.3%, and between the clade 3efg, the difference between the subtypes was 
9.4–17.2% on nucleotide level. 
2.5   Hepatitis E in humans 
HEV is considered the most important cause of hepatitis, especially in countries with suboptimal 
sanitary conditions, in the areas endemic for HEV-1 and HEV-2 in Asia, Africa, and Central 
America. A third of the world´s population has been estimated to be exposed to HEV, and Rein 
and colleagues (2012) estimated that in 2005 approximately 2.1 million cases of hepatitis E 
occurred in the HEV-1 and HEV-2 endemic areas, causing 3.4 million symptomatic cases, 70 000 
deaths and 3000 stillbirths. Since that, 2.2 million hepatitis E infections have been estimated to 
occur in India every year (Khuroo and Khuroo, 2016).  In developed countries not endemic for 
HEV-1 and HEV-2, for instance USA and Europe, sporadic cases of hepatitis E were also found, 
and they were initially believed to be related to traveling to endemic areas (Bader et al., 1991; 
Skidmore et al., 1991; Zaaijer et al., 1993; Skaug et al., 1994). However, cases that were not linked 
to traveling were also noted (Kwo et al., 1997; Zanetti et al., 1999; Pina et al., 2000), and the 
possibility of locally acquired autochthonous HEV cases in countries not endemic for HEV-1 and 
HEV-2 was suggested. The possibility of these being of zoonotic origin was raised after the 
discovery of HEV in swine in 1997 (Meng et al., 1997). The strain now known as HEV-3 was 
found to be closely related to human HEV (Meng et al., 1997; Schlauder et al., 1998). Since then, 
such non-travel-related and potentially zoonotic cases of hepatitis E have been reported in several 
other countries throughout Europe (Widdowson et al., 2003; Amon et al., 2004; Banks et al., 
2004a; Reuter et al., 2005; Colson et al., 2007a; Pérez-Gracia et al., 2007; Norder et al., 2009; 
Brost et al., 2010; Duque et al., 2012). 
 
HEV usually causes an acute, self-limiting hepatitis in humans. The incubation period is typically 
2–6 weeks, but it may range from nine days to up to two months. The symptoms of the disease are 
undistinguishable from those caused by other hepatitis viruses, especially HAV, and include fever, 
vomiting, anorexia, and jaundice. The duration of symptoms varies from a few weeks to more than 
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a month (Emerson and Purcell, 2007). Viremia starts usually two weeks after infection and lasts 
approximately 30 days, although HEV RNA has in some cases been detected in serum samples 
taken at 14 days to up to 112 days (Clayson et al., 1995b; Nanda et al., 1995; Aggarwal et al., 
2000). HEV is excreted in the feces starting approximately three weeks after the infection, and the 
shedding lasts about 30 days, although prolonged excretion of 121 days has also been documented 
(Aggarwal et al., 2000; Takahashi et al., 2007). Humoral response to the infection starts with the 
elevation of anti-HEV immunoglobulin M (IgM) antibodies, which are usually detectable for 2–3 
months after onset of symptoms (Worm et al., 2002), although in some cases they have been 
detected for as long as 6–7 months (Favorov et al., 1992; Bendall et al., 2008). Anti-HEV 
immunoglobulin G (IgG) antibodies become detectable soon after IgM and usually remain 
detectable for several years, up to at least 23 years (Arankalle et al., 1995; Mitsui et al., 2005; 
Hogema et al., 2014; Schemmerer et al., 2016),  although anti-HEV IgG concentration have been 
seen to decrease after five years (Schemmerer et al., 2016). 
 
Based on the research of locally acquired HEV cases in developed countries, it is apparent that the 
epidemiology and clinical features of hepatitis E in HEV-1 and HEV-2 non-endemic areas differ 
from those in endemic areas and that hepatitis E presents as two distinct diseases (Teshale et al., 
2010b). The disease caused by HEV-1 and HEV-2 is referred to as the endemic disease, whereas 
the disease caused by HEV-3 and HEV-4 is referred to as the sporadic or zoonotic disease. 
2.5.1   Endemic disease caused by HEV-1 and HEV-2 
In the HEV-1 and HEV-2 endemic areas, hepatitis E in humans occurs mainly as outbreaks and 
epidemics that are usually caused by fecally contaminated water sources (Balayan et al., 1983; 
Aggarwal, 2010; Kim et al., 2014). Large epidemics often appear after monsoon or rainy seasons 
and after natural disasters, such as heavy rainfall and floods, which can lead to drinking water 
being contaminated with feces and sewage (Drabick et al., 1997; Ippagunta et al., 2007), and in 
crowded refugee camps with limited access to safe water (Ahmed et al., 2013; Browne et al., 
2015). Outbreaks are most often caused by HEV-1, and they can affect thousands or even 
hundreds of thousands of people (Teshale et al., 2010b). Typically, 1–15% of a population of a 
community is affected in an HEV outbreak, although higher rates have also been reported, such as 
25% in an outbreak in Uganda in 2007–2009 (Teshale et al., 2010a). Outbreaks caused by HEV-2 
have been reported in Asia and Africa (Vélazquez et al., 1990; Maila et al., 2004). In endemic 
areas, the disease occurs most often in young adults, with males attacked more often than females 
(Aggarwal, 2011). HEV seroprevalence studies in the endemic areas have also shown that the 
seroprevalence is low in children, and then increases from the age of 15 years up to the peak at the 
age of 30 years (Rein et al., 2012). All infections are not clinical, with approximately 20–30% of 
those infected developing a symptomatic disease (Rein et al., 2012). In general, mortality during 
the epidemics is 0.2–4%, but a significantly higher attack rate of the disease occurs in pregnant 
women, who also have significantly higher mortality of 10–25% caused by fulminant hepatic 
failure, especially during the third trimester (Kumar et al., 2004). The exact reason for the 
predilection of the disease in pregnant women and the worse prognosis in this group still remain 
unknown. In addition to the fecal-oral route of infection, person-to-person transmission (Teshale et 
al., 2010a), vertical transmission from mother to fetus (Khuroo et al., 1995), and blood 
transfusion-related transmission (Khuroo et al., 2004) have also been demonstrated. Routes other 
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than fecal-oral are, however, considered to have a small overall significance in the outbreaks. For 
HEV-1, occurrence of zoonotic or foodborne infections has not been demonstrated. Human HEV-1 
and HEV-2 have been shown to be able to infect non-human primates, but not other animal species 
(Teshale et al., 2010b). In a study of Saad and colleagues (2007) HEVs isolated from horses in 
Egypt clustered together with human isolates of HEV-1, but no other study has confirmed presence 
of HEV-1 in animals. 
2.5.2   Sporadic disease caused by HEV-3 and HEV-4 
The disease caused by HEV-3 and HEV-4 in humans is typically acute and self-limiting, but the 
majority of the infections, approximately 67–98%, are asymptomatic. The symptoms of the disease 
are often milder than those caused by HEV-1 and HEV-2 and can present as flu-like symptoms 
without jaundice (Vollmer et al., 2016a). In contrast to HEV-1 and HEV-2, HEV-3 and HEV-4 do 
not cause epidemics (Teshale et al., 2010b). In addition to sporadic cases of hepatitis E, they can 
occasionally appear as small clusters of cases, which usually have food as a point source 
(Matsubayashi et al., 2008; Colson et al., 2010; Guillois et al., 2015). Their main source of 
infection is zoonotic, with pigs as their primary reservoir (Chang et al., 2009). The sporadic 
disease has not been demonstrated to be more prevalent in pregnant women, and mortality among 
pregnant women is no higher than in the general population (Vollmer et al., 2016a). 
 
In view of clinical cases being rare, surprisingly high HEV seroprevalences have been detected in 
healthy populations in HEV-1 and HEV-2 non-endemic areas. Studies on HEV seroprevalences 
among blood donors in Europe have revealed a wide range of seroprevalences from 1.3% to 52.5% 
(Boutrouille et al., 2007; Christensen et al., 2008; Mansuy et al., 2008, 2011, 2015, 2016; Masia et 
al., 2009; Kaufmann et al., 2011; Scotto et al., 2012; Vollmer et al., 2012; Juhl et al., 2013; Slot et 
al., 2013; Fischer et al., 2015; Holm et al., 2015; Lucarelli et al., 2016; O´Riordan et al., 2016; 
Ricco et al., 2016). Several studies have been conducted in France, where seroprevalences ranging 
from 3.2% (Boutrouille et al., 2007) to over 50% have been reported, and variation in the 
prevalences between different areas were observed (Mansuy et al., 2015). In Denmark, the 
seroprevalence declined with time, from 32.9% in samples collected in 1983 (Christensen et al., 
2008) to 10.7% in 2015 (Holm et al., 2015). In contrast to the seroprevalences in HEV-1 and 
HEV-2 endemic areas, increasing age has been associated with higher seropositivity rate in 
developed countries, with the peak usually occurring between 40 and 70 years of age (Lewis et al., 
2008; Mansuy et al., 2009, 2015, 2016; Petrovi? et al., 2014; Holm et al., 2015), and men more 
often seropositive and having the clinical disease than women (Buti et al., 2004; Lewis et al., 
2008; Mansuy et al., 2009;  Said et al., 2009; Meader et al., 2010; Verhoef et al., 2012). A feature 
distinct to HEV-3 is that the disease can progress to chronic hepatitis, which has been reported in 
immunocompromised patients, especially solid-organ transplant recipients. The condition can lead 
to liver fibrosis and cirrhosis and ultimately to death (Colson et al., 2011). Transfusion-related 
infections have also been documented for HEV-3 (Boxall et al., 2006; Colson et al., 2007a). Acute 
infections based on detected HEV RNA in donated serum samples have been reported among 
blood donors. Although the rates are low (< 1%), they imply potential risk of transmission to blood 
recipients (Vollmer et al., 2012; Hewitt et al., 2014; Lucarelli et al., 2016; O´Riordan et al., 2016). 
Thus, in addition to providing information about silent HEV infections in healthy persons, these 
studies on blood donors raise concern about the safety of blood products, especially for 
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immunocompromised recipients. Patients with pre-existing liver disease also have a poorer 
prognosis, with high mortality after HEV infection with all four genotypes (HEV-1–HEV-4) 
(Dalton et al., 2007; Kumar Acharia et al., 2007). 
 
In addition to developed countries, HEV-3 especially is common in swine worldwide (Cooper et 
al., 2005). Reports of persons having contact with pigs, such as swine farmers and slaughterhouse 
workers, possessing antibodies against HEV more often than those not having contact with pigs 
have also been made in the HEV-1 and HEV-2 endemic areas (Chang et al., 2009; Vivek and 
Kang, 2011; Lee et al., 2013; Jia et al., 2014; Traoré et al., 2015), suggesting that some portion of 
those infections are caused by HEV-3 and HEV-4.  
2.6   HEV in domestic swine 
Since the isolation of the swine HEV strain in 1997 (Meng et al., 1997), studies on its occurrence 
in swine populations have shown that HEV-4 and especially HEV-3,  previously often also 
referred to as the swine HEV, are enzootic in domestic pigs worldwide (Okamoto et al., 2007). 
HEV-4 was first detected in swine in Taiwan (Hsieh et al., 1999), and it has been found to be 
enzootic in swine in Japan (Takahashi et al., 2003) and in China, where it is the principal genotype 
in swine (Zheng et al., 2006; Chang et al., 2009; Liu et al., 2012). In Europe, HEV-4 was isolated 
for the first time from pigs in Belgium (Hakze-van der Honing et al., 2011). 
 
Meng and colleagues (1997) discovered that HEV is very common in pigs, as in some swine herds 
in the USA 100% of adult pigs had antibodies against HEV. In studies conducted in Europe, HEV 
RNA has been detected in the feces of pigs in up to 100% of farms investigated. In Italy, 0–48.4% 
(Costanzo et al., 2015), 31% (Caruso et al., 2016), and 100% (Di Bartolo et al., 2008) of the farms 
investigated had HEV RNA-positive pigs. Positive pigs have been detected at 38.1% of the farms 
investigated in Spain (Fernández-Barredo et al., 2006), 33.3% in Slovenia (Steyer et al., 2011), 
55% in both the Netherlands (Rutjes et al., 2007) and Denmark (Breum et al., 2010), 63.6% in the 
Czech Republic (Vasickova et al., 2009), 88–94% in Norway (Lange et al., 2016), and 100% in the 
UK (McCreary et al., 2008). 
 
Domestic pigs are usually infected with HEV after maternal antibodies, originating from 
colostrum, disappear at the age of 1–2 months (Meng et al., 1997; Kasorndorkbua et al., 2003; de 
Deus et al., 2008a; dos Santos et al., 2009; Kanai et al., 2010; Feng et al., 2011). In the literature, 
45–77% of breeding sows have been demonstrated to have IgG antibodies against HEV (de Deus 
et al., 2008a; Casas et al., 2011a). During the acute phase of the infection HEV is excreted in 
feces, starting from 1–2 weeks after infection and usually lasting for 3–4 weeks, but sometimes for 
up to 7–11 weeks (Meng et al., 1998, Halbur et al., 2001; Kasorndorkbua et al., 2004; Kanai et al., 
2010), although a shorter duration of excretion lasting only 11–17 days has also been reported 
(Bouwknegt et al., 2008b). Thus, acute infections with fecal shedding of HEV are most common in 
pigs aged 2–4 months (Cooper et al., 2005; Fernández-Barredo  et al., 2006; Leblanc et al., 2007; 
Di Bartolo et al., 2008, 2011; McCreary et al., 2008; Breum et al., 2010; Feng et al., 2011; Berto et 
al., 2012a; Caruso et al., 2016). Viremia starts approximately 2 weeks after fecal excretion of the 
virus and lasts approximately 10 days (Meng et al., 1998; Kasorndorkbua et al., 2004; Nakai et al., 
2006; Bouwknegt et al., 2009). Anti-HEV IgM antibodies are usually detected at 2 weeks and anti-
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HEV IgG antibodies at 2–3 weeks after the start of fecal shedding of HEV (Bouwknegt et al., 
2009; Casas et al., 2009). IgM antibodies stay for longer than 10 weeks, whereas IgG antibodies 
usually last for the lifetime of the pigs (Meng et al., 1997; de Deus et al., 2008a). 
 
The course of HEV antibody status and the status of markers for HEV infection starting from the 
birth of piglets have been described in the literature. In a study of Feng and colleagues (2011), 
serum samples from piglets aged 0–150 days were examined for the presence of HEV antibodies, 
HEV antigen, and HEV RNA. The first peak with 100% prevalence of anti-HEV IgG antibodies, 
without the presence of infectious markers HEV antigen and IgM antibodies, was detected at day 
15, representing the peak of maternal antibodies from colostrum (Meng et al., 1997; Feng et al., 
2011). In a study by dos Santos and colleagues (2009), all serum samples collected from newborn 
piglets before colostrum intake were negative for HEV antibodies, whereas 92.3% of the piglets 
were seropositive after 24 hours of colostrum intake, a finding supported by Kanai and colleagues 
(2010). Feng and colleagues (2011) reported that the anti-HEV antibody prevalence decreased to 
59.4% at day 60 after birth, without presence of HEV antigen, showing the disappearance of the 
maternal antibodies. The seroprevalence then increased again from 68.8% at day 75 to 100% at 
day 120, falling slightly to 96.9% at day 150. In the second peak of the seroprevalence, both IgG 
and IgM antibodies were detected, and in addition, HEV RNA was detected at days 60–120, and 
HEV antigen at days 75–150, showing that the pigs were infected at the age of 2–5 months. In a 
comparable study by Casas and colleagues (2011a), piglets developed IgM response to infection 
after the maternal antibodies declined, starting from 7 weeks of age. IgG antibodies were detected 
starting from 13 weeks of age. 
 
By the time of slaughter, production pigs are often cleared from the acute infection, but HEV RNA 
has been detected in the feces of slaughter-aged pigs, with rates ranging from 0% (Kaba et al., 
2009; Kanai et al., 2010; Casas et al., 2011a) to 7.0–41.2% (Fernández-Barredo  et al., 2006; 
Nakai et al., 2006; Leblanc et al., 2007, 2010; Di Martino et al., 2010; Di Bartolo et al., 2011; 
Berto et al., 2012a, 2012c; Gardinali et al., 2012) and in livers with rates ranging from 3% to 75% 
(Leblanc et al., 2010; Rose et al., 2011; Berto et al., 2012b; Walachowski et al., 2013; Jori et al., 
2016). It has been suggested that the duration of the acute infection is sometimes longer than 
commonly thought or that pigs become chronically infected in an environment loaded with the 
virus, possibly due to incomplete immunity (Fernández- Barredo et al., 2006). In addition, re-
infections, suggested to be due to short-lasting immunity, have also been considered possible in 
pigs (Di Bartolo et al., 2008). 
 
Pigs usually appear clinically healthy and asymptomatic during the infection (Meng et al., 1997; 
Banks et al., 2004b; Fernández-Barredo et al., 2006; Zheng et al., 2006; Di Bartolo et al., 2008). 
On a microscopic level, mild to moderate hepatitis lesions may be apparent in the liver, including 
slight to moderate mononuclear inflammatory infiltrates, mainly in the periportal areas, and slight 
multifocal hepatocellular necrosis (Meng et al., 1997; de Deus et al., 2006). The main mode of 
transmission of HEV in pigs is the fecal-oral route. Bouwknegt and colleagues (2008b) estimated 
that one infected pig is able to infect more than eight new pigs during the acute phase. HEV RNA 
has also been detected in the feces of breeding sows with rates of 16.3–21.9% (Fernández-Barredo 
et al., 2006; 2007; de Deus et al., 2008a), suggesting that sows might also be a source of infection 
for suckling piglets (Fernández-Barredo et al., 2007; Di Bartolo et al., 2008; Casas et al., 2011a). 
Despite the presence of IgG antibodies, physiological changes during pregnancy or stress caused 
by farrowing have been speculated to induce reactivation of HEV replication in sows (Fernández-
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Barredo et al., 2007; Casas et al., 2011a). A possible additional transmission route was suggested 
when HEV RNA was detected in urine of pigs (Banks et al., 2004b; Bouwknegt et al., 2009). It 
was proposed that urine might actually spread the virus more efficiently within and between pig 
pens than feces and the infection could occur orally or via droplet aspiration to the respiratory tract 
(Bouwknegt et al., 2009). Attempts to infect pigs via nasal secretions have also been made, with 
contradictory results; Andraud and colleagues (2013) demonstrated transmission between pig pens 
via nasal secretions, although the event was rare, whereas Kasorndorkbua and colleagues (2004) 
did not observe transmission via nasal secretions. In addition to pig-to-pig transmission, a 
contaminated environment, including feed and humans, might also be a transmission route of HEV 
in pigs (Di Bartolo et al., 2008). Water samples collected directly from water troughs in 16 pens 
were investigated in the study by Fernández-Barredo and colleagues (2006), and only one sample 
was positive for HEV RNA. The authors suggested that the virus might have reached the water 
trough through a pig´s snout that had previously been in contact with fecal material on the floor of 
the pen. Manure ditches from the same farms were also investigated in the study, with 50% testing 
positive for HEV RNA. 
2.7   HEV in wild boars 
In addition to domestic pigs, HEV has also been frequently isolated from wild boars. For the first 
time, it was detected in wild boars in Japan, and the genotype was the same as most frequently 
seen in production pigs, HEV-3 (Sonoda et al., 2004; Takahashi et al., 2004; Tamada et al., 2004; 
Li et al., 2005b; Nishizawa et al., 2005; Michitaka et al., 2007; Yano, 2007). Since then, isolation 
of HEV RNA from wild boars has shown that these animals are important hosts of HEV also in 
several European countries: Spain (de Deus et al., 2008b; Martelli et al., 2008), Germany (Kaci et 
al., 2008; Adlhoch et al., 2009; Vina-Rodriguez et al., 2015), where HEV RNA was also detected 
in wild boar serum samples collected already in 1995–1996 (Kaci et al., 2008), the Netherlands 
(Rutjes et al., 2010), Sweden (Widén et al., 2011; Roth et al., 2016), Italy (Caruso et al., 2015a; 
Kukielka et al., 2015; Martinelli et al., 2015; Mazzei et al., 2015; Montagnaro et al., 2015; 
Oliveira-Filho et al., 2015; Serracca et al., 2015; Di Profio et al., 2016), Portugal (Mesquita et al., 
2014a), Estonia (Ivanova et al., 2015), and Slovenia (Zele et al., 2016). Furthermore, antibodies 
against HEV, but not HEV RNA, have been detected in wild boars in Switzerland (Burri et al., 
2014). In addition to HEV-3, also HEV-4 has been detected in wild boars in South Korea (Kim et 
al., 2014) and Japan (Sato et al., 2011), along with the newly proposed genotypes HEV-5 and 
HEV-6 (Sato et al., 2011; Takahashi et al., 2011, 2014; Smith et al., 2014). 
 
While acute HEV infections are most frequent in young domestic pigs aged 2–4 months, HEV 
RNA has also been detected in adult wild boars. Acute HEV infections are, however, more 
frequent in young wild boars. In their study in Spain, de Deus and colleagues (2008b) detected 
HEV RNA-positive animals more frequently among juvenile and sub-adult wild boars, 26.3% and 
22.2%, respectively, than among adult animals, for whom the prevalence was 12.7%. Martelli and 
colleagues (2008) reported higher prevalences of HEV RNA-positive animals in Italy, the 
prevalence was highest, 34.8%, among wild boars of less than 12 months of age, whereas it was 
25.0% among those aged 24 months or older. In addition, de Deus and colleagues (2008b) 
observed that HEV infection was more frequent (22.6%) in intensively reared wild boars than in 
those reared in open systems (19.6%) or fenced systems (17.9%). Martelli and colleagues (2008) 
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suggested that the difference in age-related HEV RNA occurrence between domestic pigs and wild 
boars might be due to HEV infections becoming chronic in wild boars or continuous re-infection 
as a result of short-lasting immunity. 
2.8   Other confirmed or possible animal hosts of HEV 
The animal species other than swine, wild boar, and chicken, from which HEV RNA has been 
detected are presented in Table 2. The HEV of chicken, the avian HEV, was discovered in 2001 by 
Hasqhenas and colleagues (2001). The genome of avian HEV and the viruses of mammals are 
approximately 50% similar, and avian HEV does not infect mammals (Hasqhenas et al., 2001). 
The most important zoonotic genotype, HEV-3, has been detected in different species of deer, 
rabbit, rat, mongoose, horse, monkey, and goat. HEV-4 has been detected in several animal 
species, including deer, cattle, and sheep, in China. New genotypes of HEV and HEV-like viruses, 
with unknown zoonotic potential, have been isolated from rat, trout, bat, ferret, camel, and Asian 
musk shrew (Table 2). 
 
Even though HEV RNA has been detected in several animal species, there are also species from 
which only antibodies against HEV have thus far been detected. These species include  dogs 
(Arankalle et al., 2001; Vitral et al., 2005; Zhang et al., 2008b; Liu et al., 2009; Geng et al., 2011a; 
Liang et al., 2014; McElroy et al., 2015; Wang et al., 2016), cats (Kuno et al., 2003; Okamoto et 
al., 2004; Mochizuki et al., 2006; Peralta et al., 2009; Liang et al., 2014), buffaloes (Shukla et al., 
2007), and some deer species (Tomiyama et al., 2009). Genetic evidence of the sources of HEV 
antibodies in these species, with possible new animal strains of HEV, will probably be discovered 
in future research, adding new species into the expanding range of hosts of HEV and HEV-like 
viruses. 
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Table 2. Animal species other than swine, wild boar, and chicken, in which HEV RNA has been 
detected. 
Species Genotype Country Reference 
Japanese     
deer (sika deer) 
HEV-3 Japan Tei et al., 2003 
HEV-4 China Zhang et al., 2008a 
Mongoose HEV-3 Japan Nakamura et al., 2006 
Horse HEV-1 Egypt Saad et al., 2007 
 HEV-3 China Zhang et al., 2008b 
Reeves’  
muntjac 
ND China Zhang et al., 2008a 
Asiatic  
black bear 
HEV-4 China Zhang et al., 2008a 
Clouded      
leopard 
HEV-4 China Zhang et al., 2008a 
Tufted   
deer 
HEV-4 China Zhang et al., 2008a 
Crowned  
crane 
HEV-4 China Zhang et al., 2008a 
Silver  
pheasant 
HEV-4 China Zhang et al., 2008a 
Rabbit HEV-31 China Zhao et al., 2009; Geng et al., 
2011b; 2011c, 2013; Wang et al.,  
2013; Han et al., 2014; Xia et al., 
2015 
 HEV-31 United States Cossaboom et al., 2011 
 HEV-31 France Izopet et al., 2012 
 HEV-31 Mongolia Jirintai et al., 2012 
 HEV-31 Italy Caruso et al., 2015b 
 HEV-31 Germany Eiden et al., 20162 
 HEV-31 The Netherlands Burt et al., 2016 
Roe deer HEV-3 Hungary Reuter et al., 2009; Forgách et al., 
2010 
 ND Czech Republic Kubankova et al., 2015 
Red deer HEV-3 Hungary Forgách et al., 2010 
 HEV-3 Spain Boadella et al., 2010; Kukielka et 
al., 2015 
 ND The Netherlands Rutjes et al., 2010 
 HEV-3 Italy Di Bartolo et al., 2015b 
 ND Czech Republic Kubankova et al., 2015 
 HEV-3 Belgium Thiry et al., 2015b 
Cattle HEV-4 China Thiry et al., 2015a3; Huang et al., 
2016
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Table 2. (Continued)  
Species Genotype Country Reference 
Sheep HEV-4 China Thiry et al., 2015a3; Wu et al., 2015 
Rat C-14 Germany Johne et al., 2010a, 2010b, 2012 
 HEV-3, C-14 United States Purcell et al., 2011; Lack et al., 
2012; Debing et al., 2014 
 HEV-3 Japan Kanai et al., 2012 
 C-14 Vietnam Li et al., 2013a 
 C-14 China Li et al., 2013b 
 C-14 Indonesia Mulyanto et al., 2013, 2014 
 C-14 Denmark Wolf et al., 2013 
 ND France Ayral et al., 2015 
Cutthroat  
trout 
NA United States Batts et al., 2011 
Bat NA Africa, Central 
America, Europe 
Drexler et al., 2012 
Ferret C-24 The Netherlands Raj et al., 2012; Smits et al., 2013 
 C-24 Japan Li et al., 2015 
Monkey HEV-3 Japan Yamamoto et al., 2012 
Asian musk 
shrew 
C-14 China Guan et al., 2013 
Mink NA Denmark Krog et al., 2013 
Fox NA The Netherlands Bodewes et al., 2013 
Moose NA Sweden Lin et al., 2014, 2015; Roth et al., 
2016 
Yak HEV-4 China Xu et al., 2014 
Dromedary 
camel 
HEV-74 United Arab  
Emirates 
Woo et al., 2014 
Mouflon ND Czech Republic Kubankova et al., 2015 
Goat HEV-3 Italy Di Martino et al., 2016 
ND, not determined; NA, not assigned. 
1Rabbit HEV currently proposed to be a separate clade within HEV-3 (Vina-Rodriguez et al., 
2015). 
2HEV RNA detected in rabbit samples collected in 1989. 
3HEV RNA first detected in cattle and sheep in 2010. 
4According to the current proposed classification of the family Hepeviridae by Smith et al. (2014). 
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2.9   Hepatitis E as a zoonosis 
2.9.1   Hepatitis E infections and anti-HEV antibodies in persons who have  
           contact with animals 
Possible, though not confirmed, zoonotic HEV infections from contact with animals have been 
reported in Japan in an owner of a pet cat that was positive for anti-HEV IgG antibodies (Kuno et 
al., 2003), in France in an owner of a pet pig from which HEV RNA was detected with a 
divergence of 8% to the RNA isolated from the owner (Renou et al., 2007), and in Spain in a 
slaughterhouse worker who had no risk factor for HEV infection, including traveling abroad, 
consuming raw meat or seafood, or receiving blood transfusions, other than his occupation (Pérez-
Gracia et al., 2007). In France, acute HEV infection was reported in a medical student who 
practiced surgical procedures on 3-month-old pigs (Colson et al., 2007b).  
 
Several studies conducted in Europe have investigated HEV seroprevalence in persons who have 
contact with animals compared with control groups (Table 3). Significantly higher seroprevalences 
than in control groups have been detected in persons with exposure to swine in Spain (Galiana et 
al., 2008) and Germany (Krumbholz et al., 2012, 2014), farmers in Denmark (Christensen et al., 
2008), swine farmers in Moldova (Drobeniuc et al., 2001), pig farm workers in France (Chaussade 
et al., 2013), swine veterinarians in the Netherlands (Bouwknegt et al., 2007) and France 
(Chaussade et al., 2013), and slaughterers in Germany (Krumbholz et al., 2012). In addition, HEV 
seropositivity was associated with pig farming in the study of Christensen and colleagues (2008) 
and with close contact with swine, such as cleaning barns and assisting sows at birth, in the study 
of Drobeniuc and colleagues (2001). In Portugal, having been working with swine for more than 
16.5 years was associated with HEV seropositivity (Teixeira et al., 2016). In Norway, 
veterinarians who worked with swine were twice more likely to have antibodies against HEV than 
other veterinarians, 22% and 9% being seropositive, respectively (Lange et al., 2016). In Estonia, 
pig farmers were significantly more often seropositive than hunters (Ivanova et al., 2015).  
 
In the USA, swine veterinarians were reported to be 1.51 times more likely to be HEV seropositive 
than blood donors, 23.1–26.4% and 16.5–18.3% being seropositive, respectively (Meng et al., 
2002). In Taiwan, the risk of HEV infection of swine farmers was reported to be 3.5 times higher 
than that of the general population (Lee et al., 2013). In China, significantly higher 
seroprevalences have been found in farmers and slaughterhouse workers than in other occupations 
(Chang et al., 2009; Jia et al., 2014), and farmers and veterinarians have been found to be 
significantly more often seropositive than control subjects, the highest seroprevalence of 49.1% 
was detected in swine farmers, whereas the lowest seroprevelence, 26.5%, was detected in cattle 
farmers (Kang et al., 2016).  
 
Slaughterhouse workers have been shown to be significantly more often HEV antibody-positive 
than the control group in Germany (Krumbholz et al., 2012). At slaughterhouses, HEV has been 
detected in swab samples taken from floors and such tools as knives and belts, creating a risk of 
infection (Di Bartolo et al., 2012). In addition, HEV RNA has been found on a sample taken from 
a metal point used to hook the carcasses at a meat processing plant and knives and slicers at points 
of sale (Berto et al., 2012b).  
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Overall, studies indicate that persons in contact with pigs have a higher risk of HEV infection than 
persons not in contact with pigs or animals. However, since several studies in Europe have failed 
to find a significant difference between risk groups and controls (Table 3), contact with pigs is 
clearly not the only, and possibly not even the main risk factor for zoonotic HEV infection, and 
more studies are required to clarify the connection between exposure to pigs and risk of HEV 
infection in different occupations.  
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2.9.2   Foodborne hepatitis E infections and presence of HEV in food  
           products 
Confirmed cases of acute hepatitis E linked to consumption of cooked wild boar meat and 
undercooked deer meat in Japan (Tei et al., 2003; Li et al., 2005b), to consumption of raw figatellu 
sausage in France (Renou et al., 2014), and to eating cooked pork in Spain (Riveiro-Barciela et al., 
2015) have been reported. In these cases, 99.7–100% similar HEV sequences were obtained from 
the patient and the exact source food of the infection. The figatellu sausage is made of cold-
smoked pig liver and is traditionally consumed raw. In addition to the confirmed foodborne cases, 
cases strongly linked to, but not similarly confirmed to resulting from the eating of uncooked, 
undercooked, or grilled pig liver and intestines (Mizuo et al., 2005; Matsubayashi et al., 2008), 
grilled pork and entrails (Miyashita et al., 2012), uncooked wild boar liver (Matsuda et al., 2003), 
and grilled wild boar meat (Tamada et al., 2004; Masuda et al., 2005), have been documented in 
Japan. In the case reported by Matsuda and colleagues (2003), two men who had eaten the same 
wild boar meat developed severe cases of hepatitis E, and one of the men died of fulminant 
hepatitis. Furthermore, an acute case potentially linked to eating wild roe deer meat has been 
documented in South Korea (Choi et al., 2013). In France, three clusters of HEV cases were 
significantly associated with consumption of pig liver-based stuffing of a spit-roasted piglet 
(Guillois et al., 2015). Consumption of wild boar meat and offal was associated with 
autochthonous HEV infection in Germany in the study of Wichmann and coworkers (2008), and 
consumption of pork pie, ham, and sausages purchased from a supermarket were associated with 
indigenous HEV infection in the UK in the study by Said and coworkers (2014). In the USA, 
Cossaboom and colleagues (2016) found that eating undercooked meat was associated with HEV 
seropositivity in college students. 
 
Presence of HEV in several different foodstuffs or feedstock of food products, especially those of 
swine origin have been described in the literature. In addition to pig livers collected at 
slaughterhouses, HEV RNA has also been detected in porcine livers retrieved from grocery stores, 
with prevalences of 1.3% in the UK (Banks et al., 2010), 2% in Japan (Yazaki et al., 2003), 4% in 
Germany (Wenzel et al., 2011) as well as in Italy, Spain, and the Czech Republic (Di Bartolo et 
al., 2012), 5.7–8.8% in Canada (Wilhelm et al., 2014; 2015), 6.5% in the Netherlands (Bouwknegt 
et al., 2007), and 11% in the USA (Feagins et al., 2007). In addition to porcine livers, HEV RNA 
has also been detected in 2.5% of the 285 liver samples from hunted wild boars in France (Kaba et 
al., 2010). Furthermore, HEV RNA has been found in 3% of porcine meat samples collected at 
slaughterhouses in the Czezh Republic, Italy, and Spain (Di Bartolo et al., 2012). In France, 
different food products containing raw pig liver were investigated for the presence of HEV, which 
was detected in 25–30% of figatelli sausages and fitone, quenelle and quenelle paste, and dried or 
fresh liver sausages and in 3% of dried salted liver sausages (Pavio et al., 2014). HEV was also 
detected in 22.2% of raw and 4.3% of dry liver sausages in Italy (Di Bartolo et al., 2015a) and in 
20% of raw sausages and 22% of liver sausages in Germany (Szabo et al., 2015). In a study 
conducted on meat and meat products illegally imported to the EU by international air travelers, 
HEV RNA was detected in pork, Bovidae meat, including meat declared as beef and buffalo, sheep 
and antelope meat, poultry, and guinea pig meat (Rodríguez-Lázaro et al., 2015). To support the 
possibility of foodborne infections, Takahashi and coworkers (2012) have demonstrated that 
infective HEVs were present in porcine livers sold as food, and Berto and colleagues (2013a) have 
confirmed that infectious HEV was present in pig liver sausage. 
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Furthermore, Said and colleagues (2009) have reported that consumption of shellfish was 
associated with acute HEV infections during an outbreak on a cruise ship that returned to the UK 
after a world cruise. In the outbreak, 33 acute infections, 11 of which were symptomatic, and 192 
seropositive cases were confirmed. In China, a higher risk of HEV infection was detected in 
seafood processing workers who had direct contact with raw seafood than in those who were less 
exposed (Cui et al., 2016). The likely source of HEV contamination in mussels and shellfish is the 
water, instead of the meat being infected with the virus (Crossan et al., 2012; Donia et al., 2012; 
Gao et al., 2015; Mesquita et al., 2016). In the studies of Crossan and coworkers (2012) and 
Mesquita and coworkers (2016), HEV RNA was detected in 85% of investigated mussels in the 
UK and in 15% of those investigated in Spain, respectively, and the isolated viruses were of 
genotype HEV-3 in both studies. In addition, HEV-4 was found to be excreted in milk of HEV-
infected cows in China, suggesting a possible new source of infection (Huang et al., 2016). 
 
HEV-3 has also been detected in strawberries in Canada (Brassard et al., 2012), although the HEV 
was suspected of originating from river water used for irrigation of the strawberry field. In the 
study by Maunula and coworkers (2013), an HEV-positive pack of frozen raspberries collected 
from point-of-sale was found, but molecular analysis of the sample was not possible. HEV has also 
been found in 3% of samples collected from salad vegetables supply chain in Greece, Serbia, and 
Poland (Kokkinos et al., 2012). The likely source of HEV contamination in berries and salad is 
contaminated irrigation water. HEV has been detected in irrigation water of vegetables (Kokkinos 
et al., 2016), as well as in surface water samples (Steyer et al., 2011; Williamson et al., 2011; 
Lazi? et al., 2015; Marcheggiani et al., 2015; Givens et al., 2016) and wastewater samples 
(Masclaux et al., 2013 Beji-Hamza et al., 2015; Myrmel et al., 2015), and wastewater potentially 
contaminates the natural waters used for irrigation, in addition to seawater that contaminates 
shellfish. 
 
The results of numerous studies on several different food products demonstrate that pig- and wild 
boar-derived sources of foodborne HEV infections are common, and the meat of other animal 
species, in addition to seafood, can also be sources of infection. 
2.10   Diagnosis of hepatitis E 
When HEV was first detected, the diagnosis was based on immune electron microscopy (Bradley 
et al., 1987) and fluorescent blocking antibody assay and HEV antigen detection in hepatocytes, 
dependent on light microscopy (Krawczynski and Bradley, 1989). The diagnosis has since then 
been facilitated by the development of serological methods for anti-HEV antibody detection and 
molecular techniques for detection of HEV RNA. HEV does not replicate efficiently in vivo, and 
growing it in cell culture has proven to be extremely difficult. Thus, no efficient cell culture 
systems for HEV exist to facilitate HEV detection and diagnosis of hepatitis E, although cell 
culture models have been developed and used in replication studies (Tanaka et al., 2007; 
Takahashi et al., 2010; Berto et al., 2013b; Okamoto et al., 2013). 
 
Serological diagnosis of all four human infecting HEV genotypes, HEV-1–HEV-4, with one test is 
possible since they all belong to the same serotype (Khudyakov and Kamili, 2011), and numerous 
in-house and commercial ELISA (enzyme-linked immunosorbent assay) tests are in use in both 
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research and patient diagnosis. However, contradictory results have been reported for 
commercially available ELISA tests, demonstrating their different performance characteristics, 
including sensitivities ranging between 17% and 100% (Mast et al., 1998; Herremans et al., 2007a; 
Norder et al., 2016; Perez-Gracia et al., 2016). Immunoblot assays can be used to confirm the 
results of ELISA tests, but no consensus exists regarding their need in accurate detection of anti-
HEV antibodies. For instance, according to Herremans and colleagues (2007a), the combination of 
ELISA and immunoblot tests is essential for acceptable specificity and sensitivity in serological 
diagnosis of HEV, whereas Vollmer and coworkers (2016a) recently reported that immunoblot did 
not increase the informative value of the serological results obtained by ELISA. Furthermore, there 
is currently no gold standard for serological diagnosis of HEV, and research is needed to develop 
and provide more reliable diagnostic tests (Rossi-Tamisier et al., 2013; Krumbholz et al., 2014; 
Norder et al., 2016; Vollmer et al., 2016b). 
 
Real-time RT-PCR (reverse transcription polymerase chain reaction) is a sensitive and specific 
method for detection of HEV RNA in both sera and feces. No gold standard for PCR diagnosis of 
HEV is available, although The World Health Organization (WHO) has established a standard for 
HEV RNA, which allows comparison of different PCR assays for HEV detection (Baylis et al., 
2013). The in-house methods, as well as their sensitivities, used in research and diagnosis vary 
between tests and laboratories (Baylis et al., 2011). Furthermore, there is currently no consensus of 
which genomic region should be used for genotyping HEV. However, whole-genome sequencing 
is getting common and is preferred for classification of HEV (Liu et al., 2008). Since the viremic 
phase of HEV infection is relatively short, a negative PCR result should not be used to rule out 
HEV infection (Perez-Gracia et al., 2016). However, detecting HEV RNA, especially with 
simultaneous serological detection of anti-HEV IgM antibodies, is a sensitive and specific 
indication of an acute infection.  
2.11   Prevention of hepatitis E infections 
In HEV-1 and HEV-2 endemic areas, especially in developing countries, essential prevention 
procedures of hepatitis E infections are reducing exposure to HEV by improving sanitary 
conditions and providing clean drinking water, and inducing immunity by using vaccinations, 
which are discussed in section 2.11.1 (Kamar et al., 2012; Pérez-Gracia et al., 2015). Travelers to 
these areas should make sure to only use uncontaminated drinking water and to remember the 
basic hygienic procedures including washing hands with soap and water. 
 
To prevent foodborne HEV infections, good hygienic practices are needed in food preparation, 
starting from appropriate safety measures during storage and handling of uncooked pork –bearing 
in mind the possibility of cross-contamination from pork to the surfaces and other foodstuff 
simultaneously handled – to ensuring that meat and meat products are thoroughly cooked. In the 
study by Barnaud and colleagues (2012), complete inactivation of HEVs in paté-like preparations 
was achieved when heated at 71?C for 20 minutes. Feagins and coworkers (2008) demonstrated 
that when HEV-contaminated livers were boiled or stir-fried for 5 minutes, the virus was also 
completely inactivated, whereas inactivation was not achieved when the liver samples were 
incubated at 56?C for 1 hour. It would also be important to inform people, especially risk 
populations including pregnant women, immunocompromised individuals, and persons with liver 
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conditions, of the potential risk of hepatitis E from raw or uncooked pork, wild boar, and deer 
meat (Pérez-Gracia et al., 2015). Recently, Guerrero-Latorre and colleagues (2016) reported that 
UV disinfection and flocculation-chlorination sachets reduced HEV concentration in water. These 
and other possible measures to reduce HEV contamination in water warrant further study. 
 
In farm practices, preventive methods, such as wearing gloves and washing hands with soap and 
water, appear to reduce HEV exposure to humans (Meng, 2013; Pavio et al., 2015). In the study of 
Schielke and colleagues (2015), hunters who wore protective gloves when disemboweling wild 
boars were found to be significantly less often HEV seropositive than those who did not wear 
gloves. Wilhelm and colleagues (2016) found in their logistic regression analysis study that 
requiring shower-in from visitors to swine farms was a significant predictor of lower detection of 
HEV RNA. Wilhelm and colleagues (2016) also found that if farms obtained finisher pigs from 
several different sources, odds of HEV RNA detection from pigs increased. Further investigations 
are needed to identify the types of preventive and biosecurity measures that could be used to limit 
HEV transmission among pigs and also to clarify how HEV persists in farm surroundings to 
determine which cleaning and disinfection procedures can be used to eliminate it.  
2.11.1   HEV vaccine 
Since all four HEV genotypes infecting humans belong to the same serotype, HEV is considered a 
good candidate for vaccine development (Purcell and Emerson, 2008). Thus far, only one vaccine, 
prepared by a Chinese research group and known as HEV 239 vaccine, has been registered and 
available for use in China, under the name Hecolin (Li et al., 2005a; Zhang et al., 2009; Zhu et al., 
2010). The vaccine is based on HEV-1, and more studies are required to determine its efficacy 
against HEV-3, although it has been proven to provide protection against HEV-4 infections. WHO 
has evaluated the use of the vaccine in preventing and controlling HEV infections in terms of 
safety, immunogenicity, efficacy, and cost-effectiveness, and as a result, routine use of the vaccine 
in HEV endemic countries was not recommended. Nevertheless, countries could use it as a part of 
a prevention program in special situations, such as outbreaks of HEV, and for travelers and 
pregnant women (WHO, 2015). For prevention of zoonotic HEV infections, using vaccines in 
animals has also been considered. Liu and colleagues (2014) studied the efficacy of the Chinese 
vaccine on rabbits exposed to HEV-4 and HEV-7, and found the vaccine to be effective. Future 
research is needed to investigate the efficacy of the vaccine in other animals, especially pigs, and 
to evaluate the possibility of reducing the risk of zoonotic infections by vaccinating pigs (Meng, 
2013; Liu et al., 2014).  
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3   Aims of the study 
The objectives of this work were to investigate the occurrence of hepatitis E virus in selected 
human populations and in production swine in Finland, to investigate transmission of HEV among 
production swine during their production cycle, and to evaluate the work-related risk factors 
associated with HEV exposure in Finnish veterinarians.  
 
Specific aims were as follows: 
 
1. To investigate the occurrence and transmission of hepatitis E infections in production pigs in 
Finland, and to identify genetic divergence of HEV strains occurring in production pigs at 
different swine farms (II, III, unpublished) 
 
2. To investigate the occurrence of hepatitis E infections in selected human populations in 
Finland: in patients with unexplained acute hepatitis (I) and in veterinarians, in addition to 
evaluating the work-related risk factors associated with HEV exposure in veterinarians (IV) 
 
3. To compare the seroprevalences obtained by ELISA tests detecting total anti-HEV, anti-HEV 
IgG, or anti-HEV IgM antibodies in human serum samples (unpublished) 
 
4. To compare the sensitivity and suitability of two sets of primers and conventional RT-PCR 
methods targeting different regions of the HEV genome for sequencing and genetic 
characterization of swine HEV (unpublished) 
 
5. To examine the possibility of zoonotic swine-to-human hepatitis E infections in Finland (I–IV, 
unpublished). 
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4   Materials and methods 
4.1   Study designs, sampling, and data collection 
4.1.1   Hepatitis E infections in human patients with unexplained acute    
           hepatitis (I) 
In Study I, to investigate whether HEV is the cause of hepatitis in Finnish human patients with 
unexplained acute hepatitis, 105 serum samples, collected between March 2000 and January 2008 
from 97 patients who had all been diagnosed and treated for acute hepatitis, were selected from the 
archives of the Department of Virology, Helsinki University Hospital and tested for the presence 
of anti-HEV IgG and IgM antibodies. Of the patients, 53 were males and 44 females. The patients 
were aged 14–87 (mean 41.5) years. Sixty-two patients originated from the Helsinki and Uusimaa 
Hospital District area, and the samples from them had all been tested and found negative for HAV 
and/or HBV, and most of them also for HCV. Thirty-five patients originated from all over Finland, 
and their samples (N=43) had been tested and found positive for anti-HEV IgG antibodies. 
Samples that were found HEV antibody-positive were also tested for the presence of HEV RNA. 
Information on traveling history was available for some of the patients. 
4.1.2   Occurrence of HEV in production swine in different production stages     
           and presence of HEV at swine farms (II, III, unpublished) 
To achieve an overview of HEV occurrence in production pigs in different production stages and 
the presence of HEV at swine farms in Finland, a total of 568 fecal and/or serum samples from a 
total of 376 individual pigs, and pooled fecal samples collected from the floors of 114 pig pens 
were examined for HEV RNA, and serum samples from 249 pigs were examined for anti-HEV 
antibodies (Table 4). The samples were collected during 1998–2011 from a total of 37 separate 
swine farms: farms 1–29 (in Studies II and III, and unpublished studies) and A–H (in Study III), in 
addition to a swine test station on three occasions in 2007, 2010 (in Study III), and 2011 (in 
unpublished studies), and from a slaughterhouse in 2011 (in unpublished studies). Samples 
collected from 34 separate swine farms, in addition to the swine test station in all three occasions, 
and the slaughterhouse were examined for HEV RNA. Serum samples collected from pigs at six 
separate farms, in addition to the swine test station in 2007 and 2010, and the slaughterhouse were 
examined for the presence of anti-HEV antibodies. 
 
The sampled pigs were divided into groups according to their production stage: sucker pigs (age 
approximately 0–4 weeks), weaner pigs (age approximately 2–3 months), grower pigs (age 
approximately 3–4 months), finisher pigs (age ? 5 months), and sows (Table 4). According to the 
production stages of pigs sampled, the swine farms were categorized as farrowing farms or 
fattening farms. At farrowing farms sucker pigs and/or weaner pigs, and at fattening farms grower 
pigs and/or finisher pigs were sampled. Of the 37 separate swine farms, 28 farms were farrowing 
farms and 13 farms were fattening farms. At seven farms, pigs in both farrowing and fattening 
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stages were sampled. Only sows were sampled at three farms. Samples from sucker pigs were 
collected from six, samples from weaner pigs from 28, samples from grower pigs and finisher pigs 
both from nine, and samples from sows from four separate farms. In addition, samples from 
grower pigs were collected at the swine test station on all three occasions, and samples from 
finisher pigs at the swine test station in 2007 and 2011, and at the slaughterhouse. From 118 pigs, 
samples were collected twice or more often, up to six times, at different ages during the study. 
The swine test station from which samples of pigs during the fattening stage were collected was 
comparable with a commercial fattening farm. The station operated as a center for testing 
production traits of pigs from Finnish swine herds, and litters of pigs from all over Finland were 
sent to the station at the age of 2–3 months, which is the age the pigs are normally sent to a 
fattening farm. On arrival, the litters were divided into pens in one unit of the station in mixed 
groups that were kept stationary during a three-month raising period, which ended at slaughter at 
the age of 5–6 months. 
Table 4. Numbers of swine samples tested for HEV RNA and anti-HEV total antibodies according 
to the production stage of the pigs, together with the number of farms from which the samples 
were collected. 
Production stage and age 
of pigs from which samples 
were collected 
Numbers of types of samples tested 
Number of 
farms from 
which samples 
were collected 
Fecal and 
serum 
samples from 
individual 
pigs tested 
for HEV RNA 
Pooled fecal 
samples 
collected 
from floors of 
pens tested 
for HEV RNA 
Serum 
samples 
tested for 
anti-HEV 
antibodies 
Sucker pigs (0–4 weeks) 67 23 0 6 
Weaner pigs (2–3 months) 162 30 2 28 
Grower pigs (3–4 months) 123 36 24 121 
Finisher pig (? 5 months) 210 25 136 122 
Sows 6 0 87 4 
Total 568 114 249 413 
1Samples were collected from 9 separate swine farms, and from the swine test station on three 
occasions in 2007, 2010, and 2011. 
2Samples were collected from 9 separate swine farms, and from the swine test station on two 
occasions in 2007 and 2010, and the slaughterhouse in 2011. 
3In total, samples were collected from 37 separate swine farms of which samples from pigs in only 
one production stage were collected from 30 farms, and samples from pigs in two or more 
production stages were collected from 11 farms, and from the swine test station in three occasions 
in 2007, 2010, and 2011, and from the slaughterhouse in 2011. 
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4.1.3   Dynamics of hepatitis E infections in production swine during the  
           farrowing and fattening stages and at the time of slaughter (II, III) 
To investigate hepatitis E infections in young pigs during their farrowing stage, HEV status of pigs 
was monitored at follow-up studies at two farrowing farms (farms 1 and 2) in October–December 
2010 in Study II. Fecal samples examined for the presence of HEV RNA were collected from 20 
piglets at both farms on four occasions. At the beginning of the samplings, the piglets were aged 
2–4 weeks (mean 26 days), and the samples were collected every 2–4 weeks until the age of 10–12 
weeks or until the pigs were transferred to fattening farms. At farm 1, pigs from four litters and at 
farm 2 pigs from five litters were investigated. 
 
To examine the occurrence and transmission of HEV among pigs during their fattening stage, two 
follow-up studies, in 2007 and 2010, in which the HEV status of pigs from 8–12 weeks of age 
until 18–22 weeks of age was monitored at the swine test station, were conducted in Study III. In 
2007, 40 pigs originating from 11 farms were investigated. From them, fecal samples were 
collected on three occasions, during the pigs´ first, fifth, and 11th week at the station. In 2010, 36 
pigs originating from eight farms were examined. From them, fecal samples were collected on six 
occasions, at two-week intervals between the pigs´ first and 11th week at the station. All fecal 
samples were examined for the presence of HEV RNA. In addition, blood samples were collected 
from the pigs at the slaughterhouse at the age of 20–24 weeks, from 37 pigs in 2007 and from 27 
pigs in 2010, and examined for the presence of anti-HEV total antibodies. 
4.1.4   Genetic divergence of HEV strains occurring in production swine at  
           different swine farms (II, III, unpublished) 
For examination of genetic divergence of HEV strains occurring in production swine at different 
swine farms in Finland, phylogenetic analyses of HEV sequences obtained from samples from pigs 
from different swine farms in Studies II and III, as well as some sequences obtained in previously 
unpublished studies were used. In total, 53 sequences from the ORF1 region, encoding the RNA 
polymerase gene, and 25 sequences from the ORF2 region, encoding the structural gene of the 
HEV genome, were analyzed. From 19 samples, both ORF1 and ORF2 sequences, from 34 
samples only ORF1 sequence, and from six samples only ORF2 sequence were obtained and 
included in the analysis.  
 
The 53 ORF1 sequences, 26 of which were unique (GenBank accession numbers KJ825678–
KJ825690 (II), JN585116–JN585127 (III), and KX266169 (unpublished)) were obtained from 
samples from pigs from nine separate farms (1, 2, 5, and 7–12) and from the swine test station in 
2007 and 2010. The 25 ORF2 sequences, 18 of which were unique (GenBank accession numbers 
KJ825691–KJ825702 (II) and KX266163–KX266168 (unpublished)) were obtained from samples 
from pigs from eight separate farms (1–4, 8–10, and 12) and from the swine test station in 2007 
and 2010. From farm 1, sequences obtained from samples collected in three different years (2005, 
2009, and 2010), and from farm 2, sequences obtained from samples collected in two different 
years (2009 and 2010) were included in the analysis.  
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4.1.5   Comparison of sensitivity and suitability of two sets of primers and  
           conventional RT-PCR methods targeting different regions of the HEV  
           genome for sequencing and genetic characterization of swine HEV (II,  
           unpublished) 
The PCR and sequencing results from Study II were used to compare two sets of primers and two 
different RT-PCR methods for sequencing and genetic characterization of the swine HEVs. Primer 
pair ISP and lmR, with conventional RT-PCR method, targeted the RNA polymerase gene in the 
ORF1 region of the HEV genome, and the set of four primers, 3156–3159, with conventional 
nested RT-PCR method, targeted the structural gene in the ORF2 region of the HEV genome 
(Table 5). To compare the methods with regard to their ability and sensitivity to amplify the HEV 
RNA-positive samples for sequencing, the proportions of sequences obtained by both primer sets 
according to the Ct (threshold cycle) values of the samples in real-time RT-PCR were compared. 
The suitability of the two amplicons for genotyping swine HEV was assessed by comparing the 
results of their phylogenetic analysis. 
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4.1.6   Presence of anti-HEV antibodies in Finnish veterinarians and    
           evaluation of possible work-related risk factors associated with HEV    
           exposure in veterinarians (IV)  
In Study IV, to investigate the occurrence of hepatitis E infections among Finnish veterinarians, 
the presence of anti-HEV total antibodies was examined from serum samples from 333 
veterinarians, including veterinary students. The samples were collected during the 2009 Annual 
Veterinary Congress in Helsinki, Finland. In addition to veterinarians, 52 non-veterinarians who 
attended the congress, including veterinary nurses and product and medical sales representatives, 
also participated in the study. The samples were collected from voluntary participants after signing 
an informed consent. Samples that were positive for total HEV antibodies, as well as 93 randomly 
selected samples that tested negative for total HEV antibodies were further examined for the 
presence of anti-HEV IgM antibodies to detect possible acute infections. In addition, HEV IgM-
positive samples were further tested for the presence of HEV RNA. The study was performed 
according to the World Medical Association Declaration of Helsinki, and it was approved by the 
Ethic Committee of Helsinki University Central Hospital. 
 
To evaluate possible risk factors for hepatitis E infections related to veterinary work, an electronic 
questionnaire that covered relevant background information, including risk factors for zoonotic 
hepatitis E infection, was composed. Most of the participants of the study completed the 
questionnaire: information on occupation (veterinarian/non-veterinarian) and sex was given by all 
385 participants (333 veterinarians and 52 non-veterinarians), and further background information 
by 357 participants (310 veterinarians and 47 non-veterinarians). The veterinarians were assigned 
to job specialty categories according to their areas of work as follows: (1) municipal veterinarians, 
(2) small animal practitioners, and those who worked (3) in a slaughterhouse, (4) in a horse clinic, 
(5) in a laboratory, (6) in an office, (7) in some other area of work, and (8) those who did not 
provide data on their area of work. Some veterinarians included in categories (1) and (3)–(5) 
worked in more than one area. Most, 89.1% (147/165), of the municipal veterinarians reported 
performing farm visits. The distribution of the samples according to age, sex, occupation 
(veterinarian/non-veterinarian), and practice specialty categories of the veterinarians is presented 
in Table 6. As possible risk factors for HEV infection, occupation (veterinarian/non-veterinarian), 
sex, age, work-related contacts with pigs and wild boars, history of traveling abroad during the 
preceding five years, history of traveling to Asia, Africa, or Mexico during the previous six 
months, having ever received hospital care abroad, and eating pork were analyzed for both 
veterinarians and non-veterinarians. In addition, the veterinary job specialties, as well as needle 
sticks by a needle that had previously been injected either into any animal or a pig were analyzed 
for veterinarians only. None of the participants had been diagnosed or suspected of having 
hepatitis during the 12 months preceding the study. 
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4.1.7   Comparison of seroprevalences obtained by ELISA tests detecting   
           anti-HEV total antibodies and anti-HEV IgG antibodies in human  
           serum samples (IV, unpublished) 
For comparison of seroprevalences obtained by Axiom HEV-Ab ELISA test (Axiom GmbH, 
Bürstadt, Germany) detecting anti-HEV total antibodies and recomWell HEV IgG test (Mikrogen 
GmbH, Neuried, Germany) detecting anti-HEV IgG antibodies, a total of 130 human serum 
samples from Study IV were analyzed by both ELISA tests. The analyzed samples included 
samples that tested anti-HEV total antibody positive, in addition to randomly selected samples that 
tested negative for anti-HEV total antibodies by Axiom HEV-Ab ELISA test in Study IV, and the 
same samples were also tested by recomWell HEV IgG test. 
4.1.8   Sampling and sample storage (I–IV, unpublished) 
Fecal samples from individual pigs were collected directly from their rectums, and pooled fecal 
samples from pig pens were collected from the floors of pig pens (II, III unpublished). All fecal 
samples were collected using clean plastic gloves. Blood samples were collected at the 
slaughterhouse during bleeding (III, unpublished). All samples were transported to the laboratory 
within 24 hours in a cool box. After arrival, serum was separated from the blood samples by 
centrifugation. Serum samples of human patients with unexplained hepatitis were selected for 
testing from the archives of the Department of Virology and Immunology, Helsinki University 
Hospital, HUSLAB (I). Blood samples from veterinarians and non-veterinarians were collected 
from voluntary participants of the Annual Veterinary Congress at the congress site, after obtaining 
a signed informed consent (IV). Sera were separated from blood samples within 12 hours of 
sampling.  All fecal and serum samples were stored at –20°C until analyzed.  
4.2   Anti-HEV antibody detection (I, III, IV, unpublished) 
For detection of anti-HEV antibodies, five different ELISA tests were used: Genelabs Diagnostics 
ELISA kits (Genelabs Diagnostics Pte., Ltd., Singapore) for detection of anti-HEV IgM and IgG in 
human sera (I), Axiom HEV-Ab ELISA kit (Axiom) for detection of anti-HEV total antibodies  in 
human sera (IV) and swine sera (III, unpublished), and recomWell HEV IgM and IgG kits 
(Mikrogen) for detection of anti-HEV IgM (IV) and IgG (unpublished) antibodies, respectively, in 
human sera. In addition, two immunoblot assays for detection of anti-HEV IgM and IgG in human 
sera (Mikrogen) were used (I). All tests were performed and the cut-off values for each test 
calculated according to manufacturers´ instructions. 
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4.3   RNA extraction (I–IV, unpublished) 
The same RNA extraction method was used throughout the studies. RNA was extracted from 140 
μl of serum or 10% stool suspensions in TN (tris-sodium chloride) or PBS (phosphate-buffered 
saline) buffer using QIAamp Viral RNA Mini Kit (Qiagen GmbH, Hilden, Germany) according to 
the manufacturer´s instructions to reach a final volume of 60 μl of RNA. 
4.4   HEV RNA detection by real-time RT-PCR (I–IV, unpublished) 
Detection of HEV RNA from both human and swine samples was performed by real-time RT-PCR 
targeting a 68 base pair (bp) long fragment of the structural gene of HEV in ORF2 using primers 
HEV2F and HEV2R (Table 5). In Study I and partly in Study III, SYBR Green chemistry was 
used, and in Study II, partly in Study III and in Study IV, as well as in the unpublished swine 
studies, a modified method using TaqMan chemistry with probe JVHEVP (Table 5) was used. In 
both methods, amplification was performed with Rotor-Gene 3000 Instrument (Corbett Life 
Sciences, Sydney, Australia). In data analysis of both methods, the threshold of the PCR was set at 
0.02. A cut-off Ct of 40 was used in all parts of the study (I–IV, partly the unpublished), except in 
the comparison of sensitivity and suitability of two sets of primers and conventional RT-PCR 
methods targeting different regions of the HEV genome for sequencing and genetic 
characterization of swine HEV (unpublished), where all samples with a Ct value were analyzed.  
 
With SYBR Green chemistry, before the amplification,  reverse transcription (RT) reaction was 
performed at 42°C for 60 minutes using a reaction solution containing 2.5 ?M reverse primer 
HEV2R, GeneAmp 1 x PCR buffer containing 15 mM of MgCl2  (Applied Biosystems, Foster 
City, CA, USA), 10 mM DTT (Roche Diagnostics GmbH, Mannheim, Germany), 8.8 mM dNTP 
mix, 20 units Recombinant RNasin Ribonuclease Inhibitor (Promega Corporation, Madison, WI, 
USA), 25 units Expand Reverse Transcriptase (Roche Diagnostics), and 3 ?l of extracted RNA.  
Amplification was then carried out using 3 ?l of the synthesized cDNA, 0.5 ?M primers HEV2F 
and HEV2R, and Quantitect SYBR Green PCR Kit (Qiagen) according to the manufacturer´s 
instructions. The amplification was carried out under the following conditions: initial activation at 
95°C for 15 minutes, followed by 50 cycles of 94°C for 15 seconds, 54°C for 45 seconds, and 
72°C for 15 seconds. Melting curves were measured at 67–95°C, and products with a melting 
temperature (Tm) of 80–81°C were considered positive. 
 
With TaqMan chemistry, the amplification was carried out as one-step RT-PCR using 3 ?l of the 
synthesized cDNA, 0.9 ?M primers HEV2F and HEV2R, 0.3 ?M probe JHVEVP, and QuantiTect 
Probe RT-PCR Kit (Qiagen) according to the manufacturer´s instructions. The amplification was 
carried out under the following conditions: RT reaction at 50°C for 30 minutes, initial activation at 
95°C for 15 minutes, followed by 50 cycles of 95°C for 15 seconds, 55°C for 45 seconds, and 
72°C for 45 seconds.  
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4.5   Sequencing (I–III, unpublished) 
HEV RNA-positive samples were further amplified for sequencing using two conventional RT-
PCR methods, a nested RT-PCR (I, III, unpublished) and a one-step RT-PCR (II, III, unpublished).  
For the nested RT-PCR, two sets of primers were used: external primers ESP and EAP and 
internal primers ISP and IAP, targeting a 352-bp fragment of the RNA polymerase gene in ORF1 
(I), and external primers 3156 and 3157 and internal primers 3158 and 3159, targeting a 348-bp 
fragment of the structural gene in ORF2 (II, unpublished) (Table 5). With both primer sets, the 
first-round RT-PCR was performed using Qiagen OneStep RT-PCR Kit (Qiagen) according to the 
manufacturer´s protocol, with 0.8 ?M each of both external primers, 8 units Recombinant RNasin 
Ribonuclease Inhibitor (Promega Corporation), and 3 ?l of extracted RNA. With both primer sets, 
the RT-PCR started with an RT reaction at 50°C for 60 minutes and initial activation at 95°C for 
15 minutes. With primers ESP and EAP, the amplification then continued as follows: 35 cycles of 
94°C for 1 minute, 55°C for 1 minute, and 72°C for 1 minute, and with primers 3156 and 3157 as 
follows: 45 cycles of 94°C for 1 minute, 52°C for 1 minute, and 72°C for 1 minute. A final 
extension at 72°C for 10 minutes was carried out with both primer sets. The first-round RT-PCR 
product was then amplified in the second-round PCR. With internal primers ISP and IAP, 2.5 ?M 
each of the primers were used, and with internal primers 3158 and 3159, 0.5 ?M. Otherwise, the 
amplification was performed in both studies with HotStarTaq Plus Master Mix Kit (Qiagen) 
according to the manufacturer´s instructions, and 1 ?l of the product from the first-round PCR. The 
reaction was carried out in the following conditions: initial activation at 95°C for 5 minutes, 
followed by 30 cycles of 94°C for 1 minute, 55°C for 1 minute, and 72°C for 1 minute, with a final 
extension at 72°C for 10 minutes. 
 
With the one-step RT-PCR, primers ISP and lmR targeting a 298-bp fragment of RNA polymerase 
gene in ORF1 (Table 5) were used in amplification for sequencing. The amplification was 
performed using Qiagen OneStep RT-PCR Kit (Qiagen) according to the manufacturer´s protocol, 
with 0.8 ?M each of the primers, 8 units Recombinant RNasin Ribonuclease Inhibitor (Promega 
Corporation), and 3 ?l of extracted RNA. RT-PCR was carried out in the following conditions: RT 
reaction at 50°C for 60 minutes, initial activation at 95°C for 15 minutes, followed by 45 cycles of 
94°C for 1 minute, 55°C for 1 minute, and 72°C for 1 minute, with a final extension at 72°C for 10 
minutes. 
 
The final PCR products were separated on 2.0% or 3.5% MetaPhor agarose gel (Lonza, Basel, 
Switzerland) stained with ethidium bromide. If this was not successful, a band-stab PCR technique 
described by Bjourson and Cooper (1992) was used (II, III). Briefly, in this technique, the 
appropriate band in the agarose gel was stabbed with an injection needle, which was then dipped 
into a fresh PCR reaction mix that was prepared as in the previous PCR, without the template. 
Amplification was then carried out as in the previous PCR amplification, and after that, the 
product was separated on agarose gel. In Study III, after the one-step RT-PCR, a second-round 
PCR with the same primers using HotStarTaq Plus Master Mix Kit (Qiagen) was also used if 
needed. All PCR products that produced the expected DNA fragment were sequenced at the DNA 
Sequencing Service, Institute of Biotechnology, University of Helsinki using Applied Biosystems 
ABI3130XL Genetic Analyzer or ABI3730 DNA Analyzer. 
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4.6   Genotyping and phylogenetic analysis (I–III, unpublished) 
All sequences obtained were compared with HEV sequences in NCBI GenBank using BLASTN 
program, and with each other using BioEdit program (http://www.mbio.ncsu.edu). For 
phylogenetic trees, additional, previously reported HEV sequences available in GenBank were 
used. Multiple alignment analysis and bootstrap value calculation for the nucleotide sequences 
were conducted using ClustalW program through the IT Center for Science (CSC) (I, III), 
ClustalX 2.1 or Clustal Omega programs (http://www.clustal.org) (II), or MEGA6 (unpublished). 
The phylogenetic trees were constructed using NJplot program (I–III) or MEGA6 (the trees 
presented in Figures 1 and 2 in the thesis) with a neighbor-joining method, using Kimura´s 
correction for multiple substitutions. 
4.7   Statistical analysis (IV) 
In Study IV, where the work-related risk factors associated with HEV exposure in veterinarians 
were evaluated, the prevalences of total HEV antibody-positive subjects were compared according 
to the potential risk factors for HEV infection. Two-by-two tables and test statistics were used to 
evaluate the differences between seroprevalences. For all tests, a 2-tailed p < 0.05 was considered 
statistically significant. 
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5   Results 
5.1   Hepatitis E infections in human patients with unexplained  
        acute hepatitis (I) 
Anti-HEV antibodies were detected by both ELISA test and immunoblot in 22.7% (22/97) of the 
patients with unexplained acute hepatitis tested (Table 7). Of all serum samples tested, 27.6% 
(29/105) were found anti-HEV antibody-positive. Of the seropositive patients, 54.5% (12/22) were 
positive for only anti-HEV IgG, and 45.5% (10/22) for either anti-HEV IgM only or for both anti-
HEV IgM and IgG. HEV RNA was detected in the samples of 8.2% (8/97) of the patients tested 
(Table 7). All HEV RNA-positive samples were from patients who were also HEV-seropositive. 
Seven of the eight RNA-positive patients were also anti-HEV IgM-positive, whereas one was 
positive for only anti-HEV IgG.  The results indicated that 11 patients had acute infections, 
including the 10 patients who were positive for anti-HEV IgM antibodies in addition to the one 
positive for HEV RNA and anti-HEV IgG antibodies. Another 11 patients who were only positive 
for anti-HEV IgG antibodies had had an earlier HEV infection. Five HEV sequences were 
obtained from the eight HEV RNA-positive samples. All of the isolates belonged to genotype 
HEV-1, based on the nucleotide similarity of 97–99% they shared with HEV-1 isolates in 
GenBank. 
 
Traveling history was available for eight of the 11 patients with acute HEV infections. Seven of 
them had traveled to HEV-1 endemic areas in India, Bangladesh, Thailand, Nepal, and Vietnam, 
whereas one had traveled to Spain. Seven of the 11 patients with acute infections were males, and 
four were females; both sexes were aged 22–50 years (mean 30.7 years for males and 33.8 years 
for females). The onsets of their hepatitis symptoms had been from less than 1 week to less than 2 
months before the samplings.  
Table 7. Results of anti-HEV IgM and IgG and HEV RNA detections of patients with unexplained 
hepatitis. 
Number of       
patients = 97 
Anti-HEV antibody 
positive by ELISA    
(% of all patients) 
ELISA result 
confirmed by 
immunoblot (% of 
patients seropositive 
by ELISA) 
HEV RNA  positive by 
real-time RT-PCR  (% 
of patients confirmed 
seropositive by 
immunoblot) 
IgM and IgG positive 111 (11.3) 101 (90.9) 7 (70.0) 
IgM positive only 2 (2.1) 0 (0)2 0 (0) 
IgG positive only 231 (23.7) 12 (52.2) 1 (8.3) 
Total positive 351 (36.1) 22 (62.9) 8 (36.4) 
1For one patient who was positive for both IgM and IgG by ELISA, only the IgG positivity was 
confirmed by immunoblot. This patient is thus also included in the ‘IgG-positive only’ category, and 
thus, the total number of patients who were anti-HEV antibody-positive by ELISA is 35. 
2Insufficient sera left to perform immunoblots. 
 
 
49
5.2   Occurrence of HEV in production swine in different  
        production stages and presence of HEV at swine farms (II,  
        III, unpublished) 
In total, HEV RNA was detected in 20.7% (78/376) of individual pigs sampled (Table 8) and in 
25.4% (29/114) of pooled fecal samples collected from pig pens (Table 9). Anti-HEV total 
antibodies were detected in 86.3% (215/249) of the pigs investigated (Table 8). From 56.8% 
(21/37) of separate swine farms investigated either HEV RNA-positive or anti-HEV antibody-
positive pigs or HEV RNA-positive pooled fecal samples were found. 
 
HEV RNA-positive samples were most frequently detected among weaner pigs and grower pigs, at 
the age of 2–4 months. No HEV RNA-positive sucker pigs were observed. Of samples from 
weaner pigs 34.6% (56/162), from grower pigs 21.1% (26/123) and from finisher pigs 2.9% 
(6/210) were HEV RNA-positive. No HEV RNA-positive sows were seen. Anti-HEV antibodies 
were examined in pigs of all production stages, except sucker pigs, and seropositive pigs were 
detected in all examined stages. The seropositivity rate was 100% (2/2) in weaner pigs, 95.8% 
(23/24) in grower pigs, 87.5% (119/136) in finisher pigs, and 81.6% (71/87) in sows. 
 
HEV RNA-positive samples were detected at 50.0% (17/34) of the separate swine farms from 
which samples were examined for HEV RNA, as well as at the swine test station on all three 
occasions (2007, 2010 and 2011), and at the slaughterhouse (Tables 8 and 9). At least one HEV 
RNA-positive pig was detected at 50.0% (14/28) of separate farrowing farms, and at 53.8% (7/13) 
of separate fattening farms. HEV RNA-positive fattening-aged pigs were also detected at the 
swine test station on all three occasions, and at the slaughterhouse. Anti-HEV total antibody-
positive pigs were detected at each of the six separate farms from which samples were examined 
for antibodies, as well as at the swine test station on two occasions in 2007 and 2010, and at the 
slaughterhouse. 
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Table 9. Numbers of pooled fecal samples collected and pooled fecal samples positive for HEV 
RNA according to the farms of origin and the production stage of the pigs in the pens sampled. 
Farm  
Numbers of samples testing positive/numbers of samples tested (%) per production 
stage
Farrowing farms Fattening farms 
Total 
Sucker pigs  
(0-4 weeks) 
Weaner pigs 
(2-3 months) 
Grower pigs  
(3-4 months) 
Finisher pigs  
(? 5 months) 
1 0/4 (0.0) 3/8 (37.5) Nc Nc 3/12 (25.0) 
2 0/3 (0.0) 0/1 (0.0) 3/4 (75.0) Nc 3/8 (37.5) 
3 0/4 (0.0) 3/6 (50.0) 1/2 (50.0) Nc 4/12 (33.3) 
4 0/4 (0.0) 4/7 (57.1)  Nc Nc 4/11 (36.4) 
5 0/4 (0.0) 0/4 (0.0)  2/4 (50.0) Nc 2/12 (16.7) 
6 0/4 (0.0) 0/4 (0.0)  0/4 (0.0) Nc 0/12 (0.0) 
9 Nc Nc 2/2 (100) Nc 2/2 (100) 
Test station 
2007 Nc Nc 11/20 (55.0) 0/25 (0.0) 11/45 (24.4) 
Total 0/23 (0.0)  10/30 (33.3)   19/36 (52.8)  0/25 (0.0)  29/114 (25.4) 
5.3   Dynamics of hepatitis E infections in production swine  
        during the farrowing and fattening stages and at the time of  
        slaughter (II, III) 
During the farrowing stage (II) all pigs examined remained negative for HEV RNA between the 
ages of 2 and 6 weeks. The age of onset of fecal HEV RNA excretion varied between the two 
farms examined; at farm 2, every second pig started excreting the virus already at the age of 7–8 
weeks, whereas at farm 1, all pigs started excretion only at the age of 10–12 weeks, i.e. just before 
or at the time of transfer to fattening farms (Table 10). At that time, practically all pigs sampled at 
both farms, 96.6% (28/29), were HEV RNA-positive. On farm 2, the last sample was not available 
for 11 pigs that had already been sent to a fattening farm at the time of the delayed last sampling 
(one week delay for reasons beyond our control). In total, 87.5% (35/40) of the pigs were HEV 
RNA-positive during the study. Three pigs on farm 2 had two consecutive positive samples.  
 
During the fattening period (III) in the first follow-up conducted in 2007, 35% (14/40) of the pigs 
were HEV RNA-positive after arriving at the swine test station from different farrowing farms at 
the age of 8–12 weeks. One of the pigs remained positive four weeks later, while the rest of the 
pigs (26/40) remained HEV RNA-negative until the end of follow up, at 5–6 months of age. No 
transmission of the virus between the pigs was observed in 2007. In the second follow-up 
conducted in 2010, three pigs were HEV RNA-positive after arriving at the station at the age of 8–
12 weeks. New infections were detected after the first sampling, suggesting that transmission of 
the virus within pens occurred; six new pigs were positive on week 3 at the age of 10–14 weeks 
and five new pigs on week 5 at the age of 12–16 weeks. No positive pigs were detected beyond 
this point. In total, 38.9% (14/36) of the pigs were positive during the 2010 survey (Table 11). At 
the time of slaughter, anti-HEV total antibodies were detected in 86.5% (32/37) and 78.6% (22/28) 
of the pigs from which a serum sample was available in 2007 and in 2010, respectively. 
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Table 11. Results of HEV RNA and anti-HEV total antibody detection of the pigs included in the 
2010 follow-up study of HEV occurrence during the fattening stage at the swine test station.
 
Results of detections 
HEV RNA HEV Ab 
Pen Pig ID Farm ID 
Week 1, 
age 2–3 
months 
Week 3, 
age     
2.5–3.5 
months 
Week 5, 
age 3–4 
months 
Weeks    
7, 9, 11, 
age    
3.5–5.5 
months  
Week 14, 
age 5–6 
months 
1 1-10 B – + – –  + 
 2-10 B – – – –  + 
 3-10 B – – + –  + 
 4-10 B – – + –  + 
 5-10 B – – + –  + 
 6-10 C – – – –  + 
 7-10 E – – – –  + 
 8-10 E – – – –  + 
 9-10 G – + – –  – 
2 10-10 C – – – –  m 
 11-10 C – – – –  + 
 12-10 C – – – –  m 
 13-10 D – – – –  m 
 14-10 D – – – –  – 
 15-10 D – – – –  – 
 16-10 F + – – –  + 
 17-10 F – – – –  – 
 18-10 H + – – –  m 
 19-10 H – – – –  + 
3 20-10 A – – + –  m 
 21-10 A – – – –  – 
 22-10 A – – + –  + 
 23-10 B – + – –  m  
 24-10 C – – – –  + 
 25-10 H – – – –  m 
 26-10 G – – – –  – 
 27-10 G – – – –  + 
 28-10 H + – – –  + 
4 29-10 C – – – –  + 
 30-10 H – – – –  + 
 31-10 H – + – –  + 
 32-10 H – – – –  + 
 33-10 G – – – –  m 
 34-10 G – + – –  + 
 35-10 G – + – –  + 
 36-10 H – – – –  + 
Total number of positive 
samples/ samples taken 
3/36 
(8.3%) 
6/36 
(16.7%) 
5/36 
(13.9%) 0  
22/28 
(78.6%) 
Ab, antibodies; ID, identification; +, positive sample; –, negative sample; m, missing sample. 
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5.4   Genetic divergence of HEV strains occurring in production  
        swine at different swine farms (II, III, unpublished) 
A total of 78 partial HEV sequences obtained in Studies II and III, and in unpublished studies were 
analyzed: 53 ORF1 sequences from nine different swine farms and the swine test station from 
2007 and 2010, and 25 ORF2 sequences from eight separate farms and the test station from 2007 
and 2010. According to phylogenetic analysis and comparison with HEV sequences in GenBank, 
all sequences obtained in this study belonged to genotype HEV-3, and within it, subtype e, as 
assigned by Lu et al. (2016). In the phylogenetic trees constructed, the ORF1 sequences formed 
eight separate clusters (Figure 2), whereas the ORF2 sequences formed seven separate clusters 
(Figure 3). Between the clusters, the ORF1 sequences shared nucleotide similarities of 87.50–
93.89% and the ORF2 sequences 86.47–94.40%. Within the clusters, the ORF1 sequences shared 
nucleotide similarities of 94.91–100%, and the ORF2 sequences 95.11–100%. 
 
Of the eight clusters in the ORF1 tree (Figure 2), five clusters only included sequences from one 
farm each: all sequences from farm 1 from three different years (2005, 2009, and 2010) as well as 
all sequences from farm 2 from two different years (2009 and 2010), in addition to all sequences 
from farms 5, 7, and 11, from which sequences from one year per farm were obtained, were 
arranged as separate clusters. In three clusters, sequences from several different farms were 
included. Sequences from farm 10 and the swine test station from 2007 were both divided into two 
different clusters, whereas sequences from farms 8, 9, and 12, and the swine test station from 2010 
all belonged to one cluster each. In first of the three mixed clusters there were sequences from 
farms 10 and 12, in the second, sequences from farm 9 and the swine test station from 2007, and in 
the third, sequences from farms 8 and 10, and from the swine test station from 2007 and 2010. 
 
Of the seven clusters in the ORF2 tree (Figure 3), four clusters only included sequences from one 
farm each. As in the ORF1 tree, all sequences from farm 1 from three different years and all 
sequences from farm 2 from two different years were arranged as separate clusters. Sequences 
from farms 10 and 12 also formed clusters of their own. In three mixed clusters sequences from 
several farms were included. The sequences from the swine test station from 2007 were divided 
into two different clusters, whereas sequences from farms 3, 4, 8, and 9, and the swine test station 
from 2010 all belonged to one cluster each. The first of the mixed clusters included sequences 
from farms 3 and 4. In the second, sequences from farm 9 and the swine test station from 2007 
were included, and in the third, there were sequences from farm 8 and from the swine test station 
from 2007 and 2010. 
 
On the amino acid level, all of the ORF2 sequences encoding the structural gene of HEV were 
100% identical. The ORF1 sequences encoding the RNA polymerase gene of HEV were divided 
into six groups, between which variation of 1–4 amino acids at positions 1440 (serine or proline), 
1447 (valine or alanine), 1450 (glutamic acid or aspartic acid), 1461 (glycine or valine), and 1462 
(threonine or serine) in reference to the HEV prototype Burma strain (M73218) were observed. 
The amino acid sequences obtained from the swine test station in 2007 and 2010 in Study III were 
divided into three groups, within which the sequences shared 100% identity with each other. The 
first group was formed by four sequences obtained from pooled fecal samples from pens and from 
an individual pig from farm 11 at the test station in 2007 and it was referred to as ´the pen 2007-
like isolate´. The second group, referred to as ´the pig 2007-like isolate´, included sequences that 
57
were obtained from samples from individual pigs from farms 10 and 12 in 2007. The third group 
constituted all of the sequences from the swine test station from 2010 and the six sequences 
obtained from pooled fecal samples and samples from individual pigs from farms 8 and 10 in 
2007, and it was referred to as ´the 2010-like isolate´. Amino acid sequences from farms 2, 5, 7, 
and 9 from Study II grouped into ´the pen 2007-like isolate´, as did one previously unpublished 
sequence from farm 1 from 2005. Overall, the amino acid sequences from farm 1 were divided 
into four separate groups, as the rest of sequences from farm 1 formed three new groups: one 
sequence from 2005 formed a group of its own, as did one sequence from 2010, whereas the rest 
of the sequences from 2009–2010 grouped together. 
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Figure 2. Phylogenetic tree based on a 216-nt fragment within the RNA polymerase gene in 
ORF1, showing the 53 isolates from nine farms and the swine test station in 2007 and 2010 from 
this study, together with 14 previously reported HEV isolates of HEV-1, HEV-2, HEV-4, and HEV-3 
subtypes a–c and e–j as proposed for reference sequences by Smith et al. (2016). 
?????? Farm?1
??????????Farm?2?
??????????Farm?5?
??????????Farm?7?
??????????Farm?8?
??????????Farm?9?
??????????Farm?10?
??????????Farm?11?
??????????Farm?12?
??????????Swine?test?station?2007?
??????????Swine?test?station?2010?
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Figure 3. Phylogenetic tree based on a 268-nt fragment within the structural gene in ORF2, 
showing the 25 isolates from eight farms and the swine test station in 2007 and 2010 from this 
study, together with 14 previously reported HEV isolates of HEV-1, HEV-2, HEV-4, and HEV-3 
subtypes a–c and e–j as proposed for reference sequences by Smith et al. (2016). 
?????
???????????Farm?1?
???????????Farm?2?
???????????Farm?3?
???????????Farm?4?
???????????Farm?8?
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5.5   Comparison of sensitivity and suitability of two sets of  
        primers and conventional RT-PCR methods targeting  
        different regions of the HEV genome for sequencing and  
        genetic characterization of swine HEV (II, unpublished) 
The real-time RT-PCR, genotyping RT-PCR, and sequencing results of 61 swine fecal samples 
from Stydy II were included in comparison of sensitivity and suitability of a one-step RT-PCR 
method targeting the ORF1 region, and a nested RT-PCR method targeting the ORF2 region of the 
HEV genome for sequencing and genetic characterization of swine HEV (Table 12). From 30 
(49%) of these samples, a total of 43 sequences were obtained. The ORF1-targeting one-step RT-
PCR method yielded more (44%) positive results than the ORF2-targeting nested RT-PCR (28%). 
In total, 51% (31/61) of the HEV RNA-positive samples were positive by either one or both of the 
RT-PCR methods. An ORF1 sequence was obtained from all 27 samples that were positive by the 
ORF1-targeting primers and an ORF2 sequence from all but one (a sample with a very high Ct 
value of 44.4) of the 17 samples that were positive by the ORF2-targeting primers. Both ORF1 and 
ORF2 sequences were obtained from a total of 13 samples. 
 
Of the HEV RNA-positive samples with Ct values of less than 30, 82% (9/11) yielded a sequence 
with both the ORF1- and the ORF2-targeting primers. As the Ct values increased in an RNA load-
dependent manner, the number of sequences decreased; of the RNA-positive samples with Ct 
values 30 and above, but less than 40, 55% (16/29) gave a sequence by the ORF1-targeting one-
step RT-PCR, and only less than half of that amount, 24% (7/29), by the ORF2-targeting nested 
RT-PCR. In total, the sensitivities of 44% for the ORF1 and of 28% for the ORF2-targeting RT-
PCR showed a higher detection rate of HEV for sequencing and genotyping when the ORF1-
targeting method was used. 
 
Table 12. Results of genotyping RT-PCRs and sequencing with the ORF1-targeting and ORF2-
targeting primers of the swine fecal samples found HEV RNA-positive by real-time RT-PCR, 
according to ascending Ct values. 
 Result in genotyping RT-PCR and sequencing by the two 
primer sets 
 
Ct value in 
real-time    
RT-PCR 
Number of ORF1 
positive samples 
(%)      
Number of ORF2 
positive samples 
(%) 
Number of 
negative samples 
(%) 
Total number of 
samples tested 
20– < 30  9 (82) 9 (82) 0 (0) 11 
30– < 35  16 (55) 7 (24) 12 (41) 29 
35–40  2 (14) 0 (0) 12 (86) 14 
> 40 0 (0) 11 (14) 6 (86) 7 
Total 27 (44)2 171, 2 (28) 30 (49) 61 
1No sequence was obtained from one sample despite a positive band in the gel with the ORF2- 
targeting primers; the total number of ORF2 sequences obtained was 16. 
2In total, 43 sequences were obtained from 30 samples; both an ORF1 sequence and an ORF2 
sequence were obtained from 13 samples. 
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The ORF1 sequences formed eight separate clusters and the ORF2 sequences seven clusters. At 
the nucleotide level, the maximum difference of the ORF1 sequences within these clusters was 
2.3% (5/216 nt), and the maximum difference of the ORF2 sequences, 0.8% (2/268 nt). Among all 
clusters, the differences in the sequences were 6.0–12.6% with the ORF1 primers and 3.4–11.6% 
with the ORF2 primers. 
 
On the amino acid level, all of the ORF2 sequences were 100% identical. Between the ORF1 
sequences, variation of 1–3 amino acids in reference to the HEV prototype Burma strain (M73218) 
was observed at positions 1440 (serine or proline), 1461 (glycine or valine), and 1462 (threonine 
or serine). 
5.6   Presence of anti-HEV antibodies in Finnish veterinarians and  
        evaluation of possible work-related risk factors associated  
        with HEV exposure in veterinarians (IV) 
Of the veterinarians investigated, 10.2% (34/333) were positive for anti-HEV total antibodies. Of 
the non-veterinary participants of the study, 5.8% (3/52) were seropositive. Anti-HEV IgM 
antibodies were not detected in any of the samples that were anti-HEV total antibody-positive. 
However, one anti-HEV IgM-positive, but HEV RNA-negative sample was detected among the 93 
randomly selected anti-HEV total antibody-negative samples that were investigated. 
 
No significant difference in total HEV antibody seropositivity existed between veterinarians and 
non-veterinarians or between the sexes. Most of the seropositive subjects were females: 79.4% 
among veterinarians, 100% among non-veterinarians, and 81.1% among all subjects. The HEV-
seropositive subjects were aged between 25 and 79 years. Among veterinarians, seropositive 
females were aged between 25 and 69 years, and seropositive males between 45 and 79 years, and 
the two seropositive non-veterinarians who had provided their age were 45 and 46 years. The 
proportional number of HEV-seropositive subjects increased steadily with age from 1.6% among 
20- to 29-year-olds to 25.0% among 50- to 59-year-olds. 
 
Among veterinarians, a significantly higher seroprevalence of 17.8% (13/73) was detected among 
small animal practitioners than the seroprevalence of 8.5% (14/165) among municipal 
veterinarians or 3.6–8.7% among other job specialties (p=0.01) (Table 13).  
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The selected possible risk factors for zoonotic HEV exposure analysed are presented in Table 14. 
Approximately three of four veterinarians (74.5%) reported having had needle stick by an injection 
needle that had previously been injected into any animal, and 7.1% reported having had a needle 
stick by an injection needle that had previously been injected into a pig. Work-related contacts 
with swine and wild boars during the five preceding years had been experienced by 71.0% and 
25.1% of the veterinarians, respectively. HEV seropositivity was negatively associated with 
having had contact with swine during the preceding five years among all veterinarians (6.4% and 
18.9% with and without swine contacts, respectively; p=0.002) and among small animal 
practitioners (6.1% and 27.5% with and without swine contacts, respectively; p=0.02). However, 
conflictingly, the seroprevalence appeared to be higher in those who had experienced needle stick 
by a needle that had previously been injected into a pig than in those who had not (difference not 
statistically significant) among all veterinarians as well as among small animal practitioners. 
 
Of the non-veterinarians, 29.8% (14/47) reported having had contact with swine and 10.6% (5/47) 
with wild boars during the previous five years, but none were found to be seropositive. A majority 
of all participants, 88.5% (316/357), ate pork. Of them, 8.9% (28/316) were positive for anti-HEV 
total antibodies, which did not differ significantly from the seroprevalence of those who did not eat 
pork. Most, 95% (339/357), of all participants reported travels abroad during the preceding five 
years: 93% outside Scandinavia and 62.7% outside Europe. Only 4.2% had visited HEV-1 or 
HEV-2 endemic areas in Asia, Africa, or Mexico during the preceding six-month period. Thirty-
two participants (9.0%) reported having received hospital care abroad. Although none of these 
factors were recognized as risk factors for the presence of anti-HEV total antibodies, the 
seroprevalence appeared to be higher in those small animal practitioners who had traveled outside 
Europe than in those who had not (difference not statistically significant, p=0.06).  
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5.7   Comparison of seroprevalences obtained by ELISA tests  
        detecting anti-HEV total antibodies and anti-HEV IgG      
        antibodies in human serum samples (IV, unpublished) 
Thirty-seven samples tested anti-HEV total antibody positive with the Axiom assay in Study IV. 
Of these, 21 (57%) were positive for anti-HEV IgG antibodies with the recomWell assay (Table 
15).  In addition, 93 anti-HEV total antibody-negative samples from study IV were randomly 
selected in the analysis for anti-HEV IgG antibodies. All of these 93 anti-HEV total antibody-
negative samples were also anti-HEV IgG-negative. The proportion of IgG-positive samples was 
highest at 88% (15/17) among samples that had OD values above 3 for the Axiom assay. In 
contrast, only 40% (6/15) of the samples with OD values between 1 and 2.999 and none of the 
samples with OD values below 1 in the Axiom assay were positive for the recomWell IgG assay.  
Table 15. Results of the 130 samples included in the comparison of ELISA assays: the results of 
the anti-HEV IgG assay (recomWell) compared with the results of the anti-HEV total antibody 
assay (Axiom). 
OD, optical density. 
 Positive samples  
OD from anti-HEV total antibody assay  
 
Number 
of  
negative 
samples < 1 1–1.999 2–2.999 3–3.999 ? 4 
Total 
number 
of 
positive 
samples
Number of 
samples (%) 
5 (14) 4 (11) 11 (30) 5 (14) 12 (32) 37 (29) 93 (72) 
Number of 
positive 
samples by 
anti-HEV IgG 
assay (%) 
0 1 (25) 5 (46) 5 (100) 10 (83) 21 (57) 0 
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6   Discussion 
6.1   Hepatitis E infections in human patients with unexplained  
        acute hepatitis (I) 
Both anti-HEV IgM and IgG antibodies, indicating an acute infection, were detected in 11.5% 
(11/96) of the patients with unexplained, non-A–C hepatitis, and also HEV RNA, confirming the 
infection, in 8 (72.7%) of them. Only IgG antibodies, indicating an earlier infection, were also 
found in 11.5% (11/96) of the patients. The prevalence of acute infections was similar to those 
detected in Italy and Spain in comparable studies on patients with unexplained hepatitis: in Spain, 
IgM antibodies were present in 11.4% of 277 patients, with HEV RNA detected in 61% of the 
IgM-positive cases (Echevarría et al., 2011), and in Italy, 10.1% of 218 patients were diagnosed 
with acute infections (Zanetti et al., 1999). Somewhat lower prevalences have been reported in 
other similar European studies. 
 
In the Netherlands, evidence of acute HEV infection as the presence IgM antibodies was found in 
3.3% of the 209 examined cases by Waar and colleagues (2005), and as the presence of both IgM 
and IgG antibodies in 4.4% of the 1027 patients examined in the study by Herremans and 
colleagues (2007b), in which detection of HEV RNA confirmed the diagnosis in 51% of the cases. 
Only IgG antibodies were detected in 6.2–6.7% of the cases by Waar and colleagues (2005), and in 
4.2% of the cases by Herremans and colleagues (2007b). In Hungary, IgG antibodies were 
detected in 7.2% of 264 examined patients (Haagsman et al., 2007). In contrast, a clearly higher 
prevalence of 20.6% of acute infections with both IgM and IgG antibodies present was detected 
among 651 patients in Italy (Romanò et al., 2011). The differences between these prevalences can 
at least partly be explained by different sizes of study groups used. 
 
All five HEV sequences obtained from human patients in this study belonged to genotype HEV-1, 
the most common genotype in the traditional HEV endemic areas in Asia, Africa, and Mexico (Lu 
et al., 2006; Purcell and Emerson, 2008). Three of the patients with sequenced samples had 
recently visited these areas, which are the likely sources of their infections. Although traveling 
history was unavailable for the other two patients with HEV-1 viruses, their infections can also be 
assumed to have originated from abroad. This assumption can also be made for one patient who 
had been to Spain and whose two samples were positive for both IgM and IgG antibodies. The 
effect of traveling outside Europe was demonstrated in a study by Norder and colleagues (2009), 
which was conducted in Sweden and Denmark on patients who were selected based on recent 
traveling history and having clinical signs of hepatitis not caused by hepatitis viruses A, B, C, or 
D. In that study, distinctly higher seroprevalences than those reported for patients who were not 
specifically selected based on traveling history in the other above-mentioned studies were 
reported; 54% of the patients in Sweden and 61% in Denmark had both IgM and IgG antibodies 
against HEV. Of sequenced HEVs in that study, 89% were of HEV-1, and the traveling histories 
indicated that those infections originated outside Europe. In the study by Zanetti and colleagues 
(1999) in Italy, 77.3% of the patients with acute infections had developed symptoms of hepatitis 
after returning from HEV endemic areas, including India, Pakistan, Bangladesh, and Somalia, and 
traveling in the endemic areas was demonstrated to be the main risk factor for HEV infections. 
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The results indicate that HEV must be considered a possible causative agent of non-A–C hepatitis 
in Finland, as in several other European countries, especially when the patient has recently visited 
an HEV-1 or HEV-2 endemic area. In this study, no infections acquired in Finland or caused by 
HEV-3 were detected. Since HEV-3 infections are usually asymptomatic or only mildly 
symptomatic (Lin et al., 2000; Mizuo et al., 2005; Ohnishi et al., 2006; Purcell and Emerson, 
2008), the group of patients with acute hepatitis symptoms may have been suboptimal for finding 
HEV-3 infections. Furthermore, it is not certain whether the ELISA test used in this study was able 
to detect HEV-3 since commercial ELISA tests for HEV antibodies have been developed for use in 
endemic areas with high prevalence of infections (Zhang et al., 2002; Daniel et al., 2004; Mizuo et 
al., 2005; Waar et al., 2005). However, since 11.5% of the patients were positive for only IgG 
antibodies, indicating an earlier infection, the possibility of cases acquired in Finland cannot be 
overlooked. 
6.2   HEV in production swine in Finland (II, III, unpublished) 
6.2.1   Occurrence and dynamics of hepatitis E infections in production  
           swine and presence of HEV at swine farms (II, III, unpublished) 
An apparent overall age-related pattern of hepatitis E infections in pigs was observed in the 
studies. The youngest individual pigs shedding HEV RNA in their feces were detected at the age 
of 2–3 months, at weaner stage, the production stage at which the HEV RNA positivity rate was 
highest, 34.6%. After that, the positivity rate decreased to 21.1% at grower stage (age 3–4 months) 
and 2.9% at finisher stage (age ? 5 months). The results of HEV RNA detection from pooled fecal 
samples also showed that the HEV RNA positivity rate was highest among weaner pigs and 
grower pigs. However, the positivity rate was highest, 52.8%, among grower pigs, and lower, but 
still at the same rate as in individual pigs, 33.3%, among weaner pigs. No positive pooled samples 
from finisher pigs were observed, but these samples were only collected from the swine test station 
in 2007. The age-related pattern of HEV excretion was in line with other studies, which have 
demonstrated that fecal HEV excretion in pigs is most common at the age of 2–4 months (Cooper 
et al., 2005; Fernández-Barredo et al., 2006; Leblanc et al., 2007; Di Bartolo et al., 2008, 2011; 
McCreary et al., 2008; Breum et al., 2010; Feng et al., 2011; Berto et al., 2012a; Caruso et al., 
2016). 
 
The course of hepatitis E infections in pigs was observed in follow-up studies conducted on pigs at 
farrowing stage in Study II and at fattening stage in Study III. In Study II, the piglets at two 
farrowing farms began shedding HEV in their feces at weaner stage (age 7–12 weeks), 3–8 weeks 
after weaning, which took place at the ages of 3–4 weeks, after which the pigs were moved to 
nursery units where they were raised until transfer to fattening farms. In pigs, fecal excretion of 
HEV usually starts 1–2 weeks after infection (Meng et al., 1998; Halbur et al., 2001; 
Kasorndorkbua et al., 2004), which suggests that the first piglets in this study were most probably 
infected shortly, 1–2 weeks, after weaning. Although 25% of the piglets started to shed HEV at the 
age of 7–8 weeks, 63% of them only began shedding the virus at the age of 10–12 weeks. 
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In other longitudinal studies of fecal HEV excretion in pigs, comparable patterns of HEV excretion 
have been described. In Slovenia, the rate of RNA-positive pigs was 5.3% at sucker age, 28.6% at 
weaner age, and 26.9% at fattening stage (Steyer et al., 2011). In Spain, HEV RNA was detected 
in the feces of pigs from the age of 9 weeks onwards, most often (in 5/5 pigs investigated) at the 
age of 3–4 months (de Deus et al., 2008a). Earlier onsets of fecal excretion of HEV have also been 
reported; in Japan, the first HEV RNA detection in feces of piglets was at the age of 30 days 
(Kanai et al., 2010), in Spain in pigs aged 3 weeks (Casas et al., 2011a), and in Canada in 2-week-
old pigs (11.8%) (Leblanc et al., 2007). In the Canadian study, the detection rate then increased to 
52.9% at the age of 2 months and reached a peak of 86.2% at the age of 4.5 months (Leblanc et al., 
2007). A possible reason for the varying age of onset of the infection and shedding of the virus is 
the quantity and/or quality of colostrum providing maternal antibodies to the piglets. The amount 
of sow antibodies affects the duration of a piglet´s passive immunity to HEV (Meng et al., 1997; 
de Deus et al., 2008a; Kanai et al., 2010), the duration of which is approximately 30 days after 
birth, but in some piglets, especially those born to strongly seropositive sows, it can last up to 60 
days or even longer (Meng et al., 1997; Kasorndorkbua et al., 2003; de Deus et al., 2008a; Kanai et 
al., 2010; dos Santos et al., 2009; Feng et al., 2011). At the time of transfer to fattening farms, 
practically all pigs at the two farrowing farms examined in Study II had been infected by HEV and 
they were shedding the virus, enabling HEV transmission from farrowing farms to fattening farms.  
 
In Study III, at the beginning of follow-up during the fattening period at the swine test station, at 
the age of 2–3 months, 22.4% (17/76) of the pigs examined were shedding HEV in their feces: 
35% (14/40) in 2007 and 8.3% (3/36) in 2010. The rates of shedding at this point were lower than 
those observed at the end of the farrowing period in Study II. The difference is probably explained 
by the different farms from which the pigs originated. During the farrowing period, HEV 
infections were followed in piglets at two farms, at which HEV-positive pigs had previously been 
detected, whereas during the fattening period, pigs that originated from 11 farms in 2007 and from 
eight farms in 2010 were followed at the test station. In the beginning of the follow-ups during the 
fattening period, in 2007, HEV RNA-positive pigs from seven farms were detected, and all pigs 
from four farms were negative, whereas in 2010, positive pigs from two farms were detected, and 
pigs from six farms were all negative. 
 
In the overall study, HEV RNA or anti-HEV antibodies were detected in samples collected from 
56.8% of separate farms investigated. HEV RNA was found in samples collected from 50.0% of 
the farms examined. This suggests that there are both HEV-positive and -negative swine farms in 
Finland. Other studies in Europe have reported a vast variety of farm-level prevalence of HEV 
RNA in swine feces. In Italy, prevalences of 0–48.4% (Costanzo et al., 2015), 31% (Caruso et al., 
2016), and 100% (Di Bartolo et al., 2008) have been detected in different studies.  A prevalence of 
38.1% has been reported in Spain (Fernández-Barredo et al., 2006), 33.3% in Slovenia (Steyer et 
al., 2011), 55% both in the Netherlands (Rutjes et al., 2007) and in Denmark (Breum et al., 2010), 
63.6% in the Czech Republic (Vasickova et al., 2009), and 100% in the UK (McCreary et al., 
2008). The differences are most probably due to the different ages of the pigs sampled and the 
different numbers of farms investigated in these studies. 
 
Pig-to-pig transmission of HEV was observed in the follow-ups during the fattening period in 
Study III. New pigs shedding HEV RNA in their feces were detected after the first sampling of the 
follow-up conducted in 2010, and the pigs that were not positive until after 2–4 weeks at the swine 
test station must have been infected at the station. In two pens, no positive pigs were detected at 
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the beginning of the fattening period, but were detected only two weeks later, suggesting that the 
virus was transmitted between adjacent pens because the wall separating them allowed pigs to 
have snout contact. Andraud and colleagues (2013) demonstrated HEV transmission between pig 
pens via nasal secretions, although it was rare. In the study by Kasorndorkbua and colleagues 
(2004), transmission via nasal secretions was not shown. However, fecal material in the snout 
would create a fecal-oral route of transmission via snout contact. Nevertheless, the possibility to 
trace the spread of HEV by sequences was limited in this study, because a sequence was only 
obtained from 60% of the HEV RNA-positive samples, most probably due to different sensitivities 
of the RT-PCR methods used. The real-time RT-PCR method used for detection was more 
sensitive than the conventional RT-PCR method used for sequencing, and thus, weaker positive 
samples that were detected by the real-time RT-PCR were not detected by the less sensitive 
conventional RT-PCR. 
 
No HEV RNA-positive pigs at finisher age (5–6 months) just before slaughter were detected in the 
follow-ups in Study III. However, in the overall study, 2.9% (6/210) of samples from slaughter-
aged pigs were found HEV RNA-positive. Of the pigs with serum samples available, 84% were 
positive for anti-HEV total antibodies at the time of slaughter in Study III. Since only 43% of the 
seropositive pigs were HEV RNA-positive during the follow-ups in Study III, 57% potentially 
carried the infection at the farrowing farms, before entering the test station. The presence of 
existing antibodies at the beginning of the fattening period would also explain why no new 
infections were detected during the 2007 follow-up. Another possibility is that in some cases fecal 
shedding of the virus was not detected due to long (4–6 weeks) intervals between consecutive 
samplings in 2007, since although pigs may excrete HEV RNA in their feces for up to 7–11 weeks 
(Meng et al., 1998; Halbur et al., 2001; Kasorndorkbua et al., 2004; Kanai et al., 2010), fecal 
shedding lasting only 11–17 days has also been reported in contact-infected pigs (Bouwknegt et 
al., 2008b). In the 2010 follow-up, however, the sampling interval was two weeks, and thus, it was 
unlikely that infections were overlooked. 
 
Diverse rates of HEV RNA in the feces of slaughter-aged pigs have been reported in other studies, 
ranging from 0% (Kaba et al., 2009; Kanai et al., 2010; Casas et al., 2011a) to 7.0–41.2% 
(Fernández-Barredo  et al., 2006; Nakai et al., 2006; Leblanc et al., 2007, 2010; Di Martino et al., 
2010; Di Bartolo et al., 2011; Berto et al., 2012a, 2012c; Gardinali et al., 2012). The overall 
seroprevalence of 87.5% in slaughter-aged pigs in this study was comparable with the 
seroprevalence of 88% recently reported in Corsica, France (Jori et al., 2016), but high relative to 
other seroprevalences reported in Europe, most of which have been between 60% and 70%: 61.4% 
in Scotland (Crossan et al., 2015), 64% in Spain (Casas et al., 2011b), and 68.6% in Germany 
(Wacheck et al., 2012). A lower prevalence of 31% was found in France (Rose et al., 2011). In 
another study from France, an overall seroprevalence of almost 75% was detected, but a variation 
range of 0–40% was observed between farms (Walachowski et al., 2013). In Canada, the overall 
seroprevalence was 59.4%, but regional differences raging between 38.3% and 88.8% were noted 
(Yoo et al., 2001). A high seroprevalence of 96.9% has been reported in China (Feng et al., 2011), 
whereas the seroprevalence was only 25% in Korea (Choi et al., 2003). Thus, variation is present 
in HEV seroprevalence of slaughter-aged pigs depending on the county, the geographical areas 
within countries, the study size, and the study settings. 
 
Overall, as expected, HEV RNA was most often detected in pigs aged 2–4 months. The results 
suggest that pigs acquire HEV infection either at farrowing farms shortly after weaning or at the 
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beginning of their growing period at fattening farms, and most of them are cleared from the 
infection before slaughter. The HEV seropositivity rate remained high, over 80%, from weaners to 
sows, demonstrating that the majority of pigs in Finland are infected with HEV during their lives. 
6.2.2   Genetic divergence of HEV strains occurring in production swine at  
           different swine farms (II, III, unpublished) 
All HEV isolates obtained from swine in studies II and III, and in the unpublished swine studies 
belonged to genotype HEV-3 and within it, subtype e. The ORF1 primers amplified a fragment of 
the RNA polymerase gene of HEV at the 3´ end of ORF1. Within the eight clusters of sequences 
obtained, there was a maximum difference of 5.1% between sequences, and between the clusters, 
the nucleotide difference was 6.1–12.5%. Lu et al. (2006) determined that based on that same area 
of the HEV genome on the nucleotide level, there was a difference of 7.0–12.1% between HEV 
isolates, whereas the difference between HEV subtypes was 11.4–22.8%. Somewhat lower 
difference of 9.4–17.2% between HEV-3 subtypes e, f, and g was determined by Doceul et al. 
(2016). The highest difference, 12.5%, between clusters from this study was above the percentage 
difference determined for isolates by Lu et al. (2016), but according to phylogenetic analysis, this 
cluster clearly belonged to the same subtype 3e as the other clusters, and did not form a separate 
subtype. The ORF2 primers targeted the structural gene of HEV in the middle region of ORF2, 
and the maximum difference between the sequences within the seven clusters was 4.9%, whereas 
the difference between the clusters was 5.6–13.5%. According to Lu et al. (2006), the difference 
between isolates was 2.0–10.1% at the 5´ end and 5.6–14.8% at the 3´ end of ORF2, whereas the 
difference between subtypes was 12.6–19.8% and 12.9–19.3%, respectively. Thus, when the 
percentage nucleotide differences between the clusters of sequences from this study were 
interpreted according to the differences determined for isolate level by Lu et al. (2016), each of the 
clusters of both ORF1 and ORF2 sequences formed an isolate of their own, suggesting that a 
separate HEV isolate originated from five of the 11 separate swine farms from which sequences 
were obtained. From one of these farms sequences from the span of six years (2005–2010) all 
belonged to the same isolate.  To the author´s knowledge, a long follow-up of genetic differences 
of HEV isolates at the same farm has not been reported elsewhere. In contrast, two different 
isolates originated from one separate farm in 2007 and from the swine test station in 2007. 
 
Interestingly, all isolates originating from the samples collected from the swine test station in 2010 
belonged to the same cluster, which also contained some isolates from the test station from 2007. 
It appeared that different isolates were introduced to the test station in 2007 by pigs arriving there 
from different farms. One of the isolates then persisted at the station or was brought there again in 
2010 from several farms simultaneously. As a limitation of the study, the geographical distribution 
of the farms from which the piglet producers sent piglets to the station was not available, leaving 
the origins and possible geographical distribution of the different isolates unexplained. 
Overall, the divergence of isolates originating from separate swine farms and from the swine test 
station on two occasions suggests that genetic variations in HEV strains originating from different 
locations occurred, although all strains belonged to the same subtype e of HEV-3. This suggests 
that subtype e is the main subtype circulating among production pigs in Finland. In several other 
European countries several different subtypes of HEV-3 appear. For example, at least three 
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subtypes, c, e, and f, have been isolated from swine in both Italy and the Netherlands, and two 
subtypes, c and f, in France (Martelli et al., 2010; Di Bartolo et al., 2011; Rose et al., 2011; Lapa et 
al., 2015). 
 
As could be expected, more homogeneity was observed at the amino acid level between the 
sequences; all ORF2 sequences were identical with each other, whereas the ORF1 sequences only 
formed six separate groups, in contrast to the eight clusters formed by the nucleotide sequences. 
Most heterogeneity was seen among the amino acid sequences from farm 1, which were divided 
into four separate groups. Two sequences from 2005 differed by one amino acid from each other, 
whereas the difference between the 2005 sequences and the sequences from 2009–2010 was 2–3 
amino acids, showing that although the same HEV strain was maintained at the farm over the 
years, a maximum of three amino acids had been replaced over time.  
6.3   Comparison of sensitivity and suitability of two sets of  
        primers and conventional RT-PCR methods targeting  
        different regions of the HEV genome for sequencing and  
        genetic characterization of swine HEV (II, unpublished) 
Currently, no consensus exists regarding the genomic region that should be used for genotyping 
HEV. Recombination has been reported to be most common in the X domain, the RNA helicase, 
and the RNA-dependent RNA polymerase in ORF1 (Chen et al., 2012). The mean nucleotide 
distances over the HEV genome are relatively homogeneous, except for the area of the papain-like 
cysteine protease domain and the hypervariable region in ORF1, which peak in variability (Smith 
et al., 2013). In addition, reduced variability was found near the beginning of the HEV genome 
and in the region where ORF2 and ORF3 overlap (Smith et al., 2013). 
 
Of the primer sets and RT-PCR methods compared in this study, the ORF1-targeting one-step RT-
PCR method resulted in a higher sensitivity in detecting swine HEV for sequencing, and it was 
also faster and more practical to use than the ORF2-targeting nested RT-PCR method. Both the 
ORF1 and ORF2 regions of the HEV genome that were amplified by the primer sets compared in 
this study were representative of the full-length genome of HEV for genotyping and classification 
(Zhai et al., 2006; Xun et al., 2007). Zhai and colleagues (2006) found that the genomic region in 
the RNA-dependent RNA polymerase domain (nt 4254–4560) in ORF1 statistically substituted for 
the full-length genome of HEV for genotyping. The primer pair used in this study amplified a 
sequence that was 50 bp shorter at the 3´ end than the region described by Zhai and colleagues 
(2006), but was otherwise identical. Xun and colleagues (2007) verified that another region in the 
5´ end of ORF2 (nt 5994–6294), which was amplified by the ORF2-targeting primers in this study, 
was even more representative of the full-length genome for HEV classification. The nucleotide 
differences observed in sequences from this study showed that the amplified genomic region of 
ORF2 was more conserved than the ORF1 region, both within and between the HEV-3 subtype e 
isolates. This was also observed at the amino acid level, since the ORF2 amino acid sequences 
were all identical, whereas variation was present among the ORF1 sequences. The variation at the 
nucleotide and amino acid levels did not affect the genetic classification of the isolates, but in 
investigations requiring source tracking of the virus, amplification and sequencing of the ORF1 
region can be more beneficial. Although both the ORF1- and the ORF2-targeting RT-PCR 
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methods were equally sensitive in amplifying strongly positive samples for sequencing and 
genotyping, the ORF1-targeting method was more than twice as sensitive as the ORF2-targeting 
method when weaker positive samples were amplified. Thus, in aiming to sequence a sample with 
a Ct value higher than 30 in the real-time RT-PCR, the ORF1-targeting method would be 
preferable to yield a sequence for genotyping. Additionally, the one-step RT-PCR method used 
with the ORF1-targeted method was clearly more time-saving and more practical to use than the 
nested RT-PCR method used with the ORF2-targeted primers. Although whole-genome 
sequencing is increasingly used and is preferred for classification of HEV (Liu et al., 2008), there 
is still a need for sensitive partial-genome amplification methods, especially for samples in which 
the viral load is low, an important example being environmental samples. 
6.4   Presence of anti-HEV antibodies in Finnish veterinarians and  
        evaluation of possible work-related risk factors associated  
        with HEV exposure in veterinarians (IV) 
The 10.2% prevalence of anti-HEV total antibodies detected in Finnish veterinarians shows that 
antibodies against HEV are common in Finnish veterinarians, although the seroprevalence was 
lower than the HEV IgG seroprevalences reported for veterinarians elsewhere; in the USA, a 
seroprevalence of 21–23% (Meng et al., 2002) and in Germany 18.8% (Krumbholz et al., 2012) 
has been reported. Surprisingly, the highest seroprevalence of 17.8% was detected among small 
animal practitioners, compared with 8.5% among municipal veterinarians, most of whom visited 
farms and had contact with swine (89.1% and 85.5%, respectively). In the USA, seroprevalences 
of 30%, 23%, 22%, and 6% were reported in the veterinary job categories of industry, practicing, 
academic, and student, respectively (Meng et al., 2002). A seroprevalence of 9.9%, which was 
close to the seroprevalence of 8.5% detected among municipal veterinarians in this study, was 
reported for pet veterinarians in Portugal (Mesquita et al., 2014b). 
 
Unexpectedly, a significantly higher proportion of seropositive veterinarians was observed among 
those who had no contact with swine (18.9%) than among those who had (6.4%), contrary to the 
results from the Netherlands, where 11% of swine veterinarians and 6% of non-swine veterinarians 
were positive for HEV IgG antibodies (Bouwknegt et al., 2008a). In France, a seroprevalence of 
19.6%, which was close to the seroprevalence in those without swine contacts in this study, was 
reported for swine veterinarians (Chaussade et al., 2013). In addition, several previous studies on 
non-veterinary populations have shown that persons who have contact with swine have a higher 
risk for HEV infection than those who do not have contact with swine (Galiana et al., 2008; 
Krumbholz et al., 2012, 2014; Chaussade et al., 2013). However, a wide range of HEV 
seroprevalences in European countries has been reported for persons who come into contact with 
swine, from HEV IgG prevalence of 3.3% in pig breeders in Italy (Vulcano et al., 2007) and 
13.4% in pig farm workers in Estonia (Ivanova et al., 2015) to HEV seroprevalence of 51.1% in 
swine farmers in Moldova (Drobeniuc et al., 2001). Moreover, 50.4% of all farmers were HEV 
antibody-positive in Denmark (Christensen et al., 2008). This shows that the variation occurs 
depending on the country and the population selected, in addition to the variety of diagnostic tests 
used for the studies, emphasizing the need to develop a gold standard for HEV antibody testing 
and comparison of test results, especially in regions with low seroprevalence. 
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There were also other factors that may have influenced the results, the main one being that all 
Finnish veterinarians have contacts with swine at some point during their careers, at least during 
their veterinary studies. HEV IgG antibodies have been reported in individuals for up to 23 years 
after they had an infection (Hogema et al., 2014). Of the 22 veterinarians who reported having had 
no contact with swine, four paradoxically stated having had needle stick by a needle that had 
previously been injected into a pig, and two of these individuals were seropositive. This suggests 
that some seropositive subjects who had not had contact with swine during the five years 
preceding the survey might have indeed contracted the infection from contact with swine that 
occurred even earlier. Additionally, the questionnaire did not contain specific questions about 
contacts with pet pigs or mini pigs, which may be treated by small animal practitioners, and from 
which a possible zoonotic infection has been reported (Renou et al., 2007). 
 
Contradictory to swine contacts, the seroprevalence appeared to be higher in those who had had a 
needle stick by a needle that had previously been injected into a pig than in those who had not, 
22.7% and 9.0%, respectively, which suggests that a possible contact with blood or tissue fluid 
from swine might be a risk factor for HEV infection. The seroprevalences among veterinarians 
who had and who had not reported a needle stick by a needle previously injected into an animal 
were 11.3% and 6.3%, respectively. The difference appears similar to the difference reported in 
the USA, where 25% and 15% of veterinarians who had and who had not reported needle stick 
were seropositive, respectively (Meng et al., 2002). 
 
Traveling abroad was reported by the majority of the subjects (95.0%), and more specifically, 
more than half (62.5%) had traveled to non-European destinations during the five years preceding 
the survey. Traveling history may at least partly explain the high HEV seroprevalence detected 
among small animal practitioners since 23.1% of those who had traveled to non-European 
destinations were seropositive, in contrast to only 4.8% of those who had not, although the 
difference was not significant. Moreover, in general, the possibility of HEV infections being 
contracted abroad cannot be disregarded since traveling history during only the preceding five 
years was inquired, and HEV IgG antibodies remain detectable much longer (Hogema et al., 
2014). 
 
Although the difference in seroprevalence between veterinarians and non-veterinarians was not 
statistically significant, it is similar to the findings of several earlier studies conducted in Europe. 
In Sweden, HEV seroprevalence of 13.0% was reported for swine farmers and 9.2% for a control 
population (Olsen et al., 2006). In Germany, seroprevalences of 18.8% among veterinarians, 
15.5% among blood donors (Krumbholz et al., 2012), and, depending on the diagnostic test used, 
13.2–32.8% among individuals in contact with swine, and 7.7–21.7% among those without such 
contact (Krumbholz et al., 2014) have been reported. However, it is important to note that the 
group of non-veterinarians in this study could not be considered a proper control group since it 
included persons with some contact with animals and also at approximately 14% of the whole 
study population the number of non-veterinarians was small. In addition, the aim of this study was 
not to compare HEV seroprevalences between veterinarians and non-veterinarians, but to compare 
HEV exposure in veterinarians working in different practice specialties. Thus, further studies are 
required to define the HEV antibody prevalence difference between veterinarians and other 
occupational groups in Finland. The overall age-related pattern observed in this study whereby the 
HEV seroprevalence increased with age was in line with the results of previous studies (Meader et 
al., 2010; Carpentier et al., 2012; Rapicetta et al., 2013). 
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One HEV IgM-positive subject was found among those who tested negative for total HEV 
antibodies, and the sample was also negative for HEV IgG antibody and HEV RNA. It is known 
that IgM antibodies appear alone for a short time at the beginning of an acute HEV infection 
before IgG antibodies manifest, simultaneously with peak viremia (Kamar et al., 2012). However, 
this sole finding of HEV IgM antibodies, which might suggest an early phase of an acute infection, 
remained unconfirmed. Since no acute infections by the presence of HEV RNA that would have 
allowed the determination of the genotype of the HEV were found, it was not possible to confirm 
whether some of the infections could have been zoonotic or autochthonous either. 
 
Overall, the results suggest that direct contact with swine is probably not the only route of HEV 
infection in veterinarians, and that multiple factors, including traveling outside Europe and 
reservoirs of HEV other than pigs, should be considered when investigating the sources of HEV 
infections for veterinarians. HEV seroprevalence in the general population in Finland has not yet 
been studied, and thus, investigation of whether Finnish veterinarians have a higher HEV 
seroprevalence than the general population is a future topic of interest. This would provide a basis 
for comparison to evaluate the significance of veterinary work as a risk factor for HEV infection in 
Finland.  
6.5   Comparison of seroprevalences obtained by ELISA tests  
        detecting anti-HEV total antibodies and anti-HEV IgG  
        antibodies in human serum samples (IV, unpublished) 
In comparison of the ELISA test results of the 130 samples selected from Study IV, 28.5% and 
16.2% were positive for the Axiom total HEV antibody assay and the recomWell HEV IgG assay, 
respectively. The results resemble those from a previous study in which the same assays were 
compared, which yielded respective figures of 27.9% and 13.8% (Krumbholz et al., 2014). The 
expected sensitivity of the Axiom assay according to the manufacturer is 83%. A sensitivity of 
96.3% and a specificity of 98.2% for the recomWell IgG assay in an acute infection setting are 
reported by its manufacturer. The Axiom assay detects total antibodies against HEV (IgM, IgG, 
and possibly also IgA). It is therefore logical that the Axiom assay yielded more positive results 
than the recomWell assay, as the latter detects only HEV IgG antibodies. The results of the 
comparison of the HEV ELISA assays are in line with other studies in which variation between 
results of different HEV ELISA tests have been observed (Rossi-Tamisier et al., 2013; Krumbholz 
et al., 2014; Norder et al., 2016; Vollmer et al., 2016b), highlighting the need for developing a 
gold standard for HEV antibody detection. 
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6.6   Possibility of zoonotic swine-to-human hepatitis E infections  
        in Finland (I–IV, unpublished) 
The study demonstrated that pigs were commonly shedding HEV at the time of transfer to 
fattening farms, potentially transferring the virus from farrowing farms to fattening farms, and 
thus, creating a possible risk of infection for pig handlers. Presence of antibodies against HEV has 
been associated with occupational history of cleaning pig barns and assisting sows at birth in 
Moldova (Drobeniuc et al., 2001) and with pig farming in Denmark (Christensen et al., 2008). In 
addition, in Estonia, HEV seroprevalence in pig farm workers was significantly higher than that in 
hunters (Ivanova et al., 2015). 
 
HEV-infected pigs that arrive at fattening farms may infect pigs arriving there from HEV-
unexposed farms. Although only a few HEV RNA-positive finisher pigs were detected in the 
study, infection at a later age during the fattening stage must be considered possible, which 
constitutes a risk for HEV entering the food chain in pork and pork-derived products at the time of 
slaughter. In several other countries this risk has been demonstrated by finding HEV RNA, in 
addition to feces, also in the livers of slaughtered pigs as well as in pig livers sold in retail shops, 
with varying prevalences. In the UK, 3% of livers collected at a slaughterhouse (Berto et al., 
2012b) and 1.3% of those collected from retail shops were positive (Banks et al., 2010). In 
Canada, the corresponding prevalences were 21% (Leblanc et al., 2010) and 5.7–8.8% (Wilhelm et 
al., 2014; 2015), respectively. In France, 0–75% of livers collected at slaughterhouses were 
positive, depending on the farm from which the pigs originated (Rose et al., 2011; Walachowski et 
al., 2013; Jori et al., 2016). Of pig livers collected from retail shops, 4% in Germany (Wenzel et 
al., 2011), 6.5% in the Netherlands (Bouwknegt et al., 2007), and 11.0% in the USA (Feagins et 
al., 2007) were positive. Moreover, HEV RNA was detected in 44.4% of serum samples from 
slaughtered pigs in Scotland (Crossan et al., 2015). HEV RNA has also been detected in swab 
samples from slaughterhouse workers (Berto et al., 2012b) and slaughterhouse floors as well as in 
surface swab samples from slaughterhouse tools such as knives and belts (Di Bartolo et al., 2012), 
a metal point used to hook the carcasses at a meat processing plant, and knives and slicers at points 
of sale (Berto et al., 2012b). Slaughterhouse workers have been shown to be significantly more 
often HEV antibody-positive than the control group (Krumbholz et al., 2012). The true 
significance of this risk in Finland requires further studies on HEV occurrence in slaughter-aged 
pigs and pork-derived foodstuff. In addition, it is still unclear how HEV persists in farm 
surroundings, and thus, examination of transportation vehicles of HEV and means of prevention of 
the infection in the swine production chain, starting with assessment of the types of control 
measures that could be used to reduce HEV occurrence and transmission on farrowing farms, is 
warranted. 
 
No confirmed zoonotic HEV-3 infections acquired in Finland were detected in humans in this 
study. However, an acute, symptomatic, and locally acquired human case of HEV-3 infection has 
been diagnosed in Finland (Kettunen et al., 2013), which demonstrated that the zoonotic HEV-3 
common in swine also infects humans in Finland. Finnish veterinarians commonly have antibodies 
against HEV, and although the results of the analysis of possible risk factors of HEV infection 
were contradictory, they suggested that contact with blood or tissue fluid from swine might be a 
risk factor for HEV infection of veterinarians. The fact that antibodies against HEV, and thus, 
HEV infections are highly common in production pigs in Finland suggests that swine may play a 
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role in the HEV infections of humans. However, the significance of these observations requires 
more detailed studies for confirmation. Further studies are also needed to investigate whether 
veterinary work constitutes a risk factor for HEV infection in Finland, as veterinarians have been 
demonstrated to have antibodies against HEV more often than control groups in studies conducted 
in the USA (Meng et al., 2002), the Netherlands (Bouwknegt et al., 2008a), and France (Chaussade 
et al., 2013). 
 
Diagnosing acute HEV-3 infections in humans is challenging because of their often asymptomatic 
or mildly symptomatic and self-limiting nature in otherwise healthy persons (Kamar et al., 2012), 
which is why infected individuals may fail to contact healthcare. Nevertheless, since these 
infections can have severe outcomes especially in immunocompromised individuals (Kamar et al., 
2008; Dalton et al., 2009); acute or subacute liver failure in patients with pre-existing liver disease 
and chronic infections in organ transplant recipients (Kamar et al., 2012), and can also cause 
serious illness in otherwise healthy persons (Kettunen et al., 2013), controlling the risk of zoonotic 
and foodborne HEV infections is important. In Finland, the possibility of HEV infection should be 
taken into account when diagnosing human patients with hepatitis symptoms, and since HEV is 
very common in pigs, the possibility of locally acquired and zoonotic human hepatitis E cases 
should not be overlooked. 
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7   Conclusions 
Hepatitis E virus is present in Finland. HEV-3 subtype e is common in production pigs, and the 
majority, 85.2%, of slaughter-aged pigs and sows have antibodies against HEV. Finnish 
veterinarians commonly have antibodies against HEV, with apparent seroprevalence of 10.2%, and 
markers for hepatitis E infection were present in 27.6% of human patients diagnosed with 
unexplained acute hepatitis, with markers for acute hepatitis E infection in 11.3% of the patients. 
 
Pigs were infected either at the end of the farrowing period on farrowing farms or at the beginning 
of the fattening period on fattening farms, at an age of 2–3 months, when the prevalence of HEV 
RNA-positive pigs was at its peak, 34.6%. Pigs excreted HEV in their feces until approximately 4 
months of age, and only 2.9% of HEV RNA-positive slaughter-aged pigs were detected, 
suggesting that pigs are usually cleared from the infection by this time. There seems to be both 
HEV-positive and -negative swine farms in Finland, and HEV-3 subtype e isolates from different 
farms formed genetic clusters of their own. When HEV RNA-negative pigs were transferred to the 
swine test station, where they came into contact with HEV RNA-positive pigs, pig-to-pig 
transmission of the infection was observed. This may indicate that infection at a later age during 
the fattening stage must also be considered possible, constituting a risk for HEV entering the food 
chain in pork and pork-derived products at the time of slaughter. In addition, common shedding of 
HEV in the feces of pigs at the time of transfer from farrowing to fattening farms creates a 
possible risk of zoonotic infection for pig handlers. 
 
Among veterinarians, surprisingly, HEV seropositivity was associated with working as a small 
animal practitioner and negatively associated with having contacts with swine. However, the 
seroprevalence appeared to be higher in those who had had needle stick by a needle previously 
injected into a pig than in those who had not, suggesting that contact with blood or tissue fluid 
from swine might be a risk factor for HEV infection. No confirmed zoonotic or autochthonous 
HEV-3 infections in humans were detected. From patients with unknown acute hepatitis, five 
isolates of HEV-1 were obtained, and the fact that most of the patients with acute infection had 
recently visited HEV-1 endemic areas in Asia, Africa, or Mexico indicated that the infections were 
obtained during travels. Traveling outside Europe should be considered when investigating the 
sources of HEV infections of veterinarians, too, since the seroprevalence appeared to be higher 
among those small animal practitioners who had traveled outside Europe than among those who 
had not. Thus, although pigs seem to play a role in the hepatitis E infections of veterinarians, direct 
contact with pigs is probably not the only HEV exposure, but possibly multiple factors, also 
including HEV reservoirs other than pigs, are involved. 
 
HEV must be considered a possible cause of acute hepatitis in humans in Finland, especially in 
patients who have returned from HEV-1 and HEV-2 endemic areas, but the possibility of locally 
acquired zoonotic hepatitis E infections should not be overlooked. However, the true significance 
of the risk of zoonotic and foodborne hepatitis E infections in Finland requires further studies on 
HEV occurrence in slaughter-aged pigs and pig-derived foodstuff, in addition to other animal 
reservoirs of HEV, especially in wild boars and deer.  
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